RESEARCH POSTER PRESENTATIONS SESSION I: Monday, 5 November 2012

Click on the topic below to view posters

SESSION I – MONDAY, 5 NOVEMBER
SET-UP: Monday, 5 November 2012, 8:30 – 8:45
POSTER DISPLAY HOURS: Monday, 5 November 2012, 8:45 - 14:15
POSTER AUTHOR DISCUSSION HOUR: Monday, 5 November 2012, 13:15 – 14:15
DISMANTLE: Monday, 5 November 2012, 14:15

HEALTH CARE USE & POLICY STUDIES – Consumer Role In Health Care

PHP1

INCORPORATING THE PATIENT'S VOICE INTO THE ASSESSMENT OF MEDICAL DEVICES: A COMPARISON OF THE UNITED STATES AND EUROPE

 

Doward L1, Whalley D2, Houghton K2, DeMuro C3, Evans E3, Gnanasakthy A4
1RTI Health Solutions, Manchester, Manchester, UK, 2RTI Health Solutions, Manchester, UK, 3RTI Health Solutions, Research Triangle Park, NC, USA, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

PHP2

EVALUATION AND COMPARISON OF PHARMACOVIGILANCE SYSTEMS IN 70 DIFFERENT COUNTRIES FOR CONSUMER REPORTING OF ADVERSE DRUG REACTIONS

 

Abdul Razack HI1, Sree V2
1Accenture Services Ltd., Bangalore, Bangalore, India, 2Chalapathi Institute of Pharmaceutical Sciences, Guntur, Andhra Pradesh, India

PHP3

INTEGRATION OF EVIDENCE ON PATIENT PREFERENCES IN HEALTH CARE DECISION MAKING: CURRENT STATE OF PLAY

 

Utens CM1, van der Weijden TD2, Joore MA1, Dirksen CD1
1Clinical and Medical Technology Assessment, Maastricht University Medical Centre; CAPHRI, Maastricht University, Maastricht, The Netherlands, 2CAPHRI, School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands

PHP4

FINANCIAL PENALTIES FOR IMPROVING DRUG ADHERENCE

 

Rottenkolber D
Ludwig-Maximilians-Universität München, Munich, Germany

PHP5

USE OF HEALTH SERVICES AND MEDICINES AMONG STUDENTS IN SERBIA

 

Višnjić A, Jović S, Miošević Z, Stojanović M, Veličković V
University in Nish, Medical Faculty, Niš, Serbia and Montenegro

PHP6

COMPARING THE EFFECTIVNESS OF DIFFERENT EDUCATIONAL PROGRAMS FOR CHILDREN ON APPROPRIATE ANTIBIOTIC USE

 

Soleymani F1, Mohamadhosseini N2
1Tehran University of Medical Sciences, Tehran, Iran, 2Ministry of Health, Tehran, Iran

HEALTH CARE USE & POLICY STUDIES – Diagnosis Related Group

PHP7

HOW DO REIMBURSEMENT SYSTEMS ENCOURAGE OR INHIBIT ADOPTION OF INNOVATIVE MEDICAL DEVICES IN AN AMBULATORY SETTING?

 

Wilkinson G1, Drummond M2
1London School of Economics and Political Science, London, UK, 2University of York, Heslington, York, UK

HEALTH CARE USE & POLICY STUDIES – Disease Management

PHP8

A SURVEY OF “JOINT WORKING” BETWEEN THE PHARMACEUTICAL INDUSTRY AND THE NATIONAL HEALTH SERVICE IN THE UNITED KINGDOM

 

Lockwood C1, Marinoni G1, Ando G2
1IHS, London, UK, 2IHS Global Insight, London, UK

HEALTH CARE USE & POLICY STUDIES – Drug/Device/Diagnostic Use & Policy

PHP9

DRUG PRICING IN BOSNIA AND HERZEGOVINA

 

Catic T, Begovic B
ISPOR Bosnia and Herzegovina Regional Chapter, Sarajevo, Bosnia

PHP10

THE EFFECT OF LAW FOR ECONOMICAL USE OF MEDICATIONS 2006 ON THE AVERAGE TURNOVER OF COMMUNITY PHARMACIES BETWEEN 2007-2010

 

Boncz I1, Donka-Verebes É2, Oberfrank F3
1University of Pécs, Pécs, Hungary, 2Integra Consulting zRt., Budapest, Hungary, 3Institute of Experimental Medicine (IEM)., Budapest, Hungary

PHP11

AVAILABILITY AND PRICING OF INNOVATIVE PHARMACEUTICALS IN THE TOP 5 EUROPEAN PHARMACEUTICAL MARKETS

 

Reinaud F1, Ando G2
1IHS, Paris, France, 2IHS Global Insight, London, UK

PHP12

PATENTED DRUG EXTENSION STRATEGIES ON HEALTH CARE SPENDING: A COST-EVALUATION ANALYSIS

 

Vernaz N1, Haller G1, Girardin F1, Huttner B1, Dayer P1, Muscionico D2, Salomon JL2, Bonnabry P1
1University of Geneva Hospitals, Geneva, Switzerland, 2OFAC, Geneva, Switzerland

PHP13

THE EFFECT OF LAW FOR ECONOMICAL USE OF MEDICATIONS 2006 ON THE NUMBER OF PHARMACIES BETWEEN 2007-2010

 

Boncz I1, Donka-Verebes É2, Oberfrank F3
1University of Pécs, Pécs, Hungary, 2Integra Consulting zRt., Budapest, Hungary, 3Institute of Experimental Medicine (IEM)., Budapest, Hungary

PHP14

2010-2012 GLOBAL HEALTH CARE REFORMS AND THEIR IMPACT ON PRICING, ACCESS AND HEALTH OUTCOMES STRATEGY

 

Aggarwal S
Novel Health Strategies, Bethesda, MD, USA

PHP15

THE IMPACT OF ORPHAN DRUG INCENTIVES ON INNOVATION AND PRICING IN NICHE THERAPEUTIC MARKETS: A SYSTEMATIC REVIEW OF THE LITERATURE

 

Kapur AK
Boston Healthcare Associates, Inc., Boston, MA, USA

PHP16

GENERIC DRUG MARKET ACCESS IN JAPAN

 

Yoshida E1, Toumi M2
1Creativ-Ceutical Ltd, London, UK, 2University Claude Bernard Lyon 1, Lyon, France

PHP17

ROLE OF SUBGROUP ANALYSES FOR TECHNOLOGY ASSESSMENT AND COVERAGE DECISIONS

 

Aggarwal S
Novel Health Strategies, Bethesda, MD, USA

PHP18

THE EFFECT OF LAW FOR ECONOMICAL USE OF MEDICATIONS 2006 ON THE CATCHMENT POPULATION OF COMMUNITY PHARMACIES BETWEEN 2007-2010

 

Boncz I1, Donka-Verebes É2, Oberfrank F3
1University of Pécs, Pécs, Hungary, 2Integra Consulting zRt., Budapest, Hungary, 3Institute of Experimental Medicine (IEM)., Budapest, Hungary

PHP19

COMPREHENSIVE VALUE ESTIMATION OF ADALIMUMAB-BASED TREATMENTS: COVET STUDY

 

Marcellusi A1, Gitto L1, Giannantoni P1, Russo S2, Favato G3, Mennini FS1
1University of Rome, Rome, Italy, 2University of Rome , Rome, Italy, 3Kingston University, Kingston, UK, Kingston, UK

PHP20

ANALYSIS OF HOW PAYERS INCORPORATE HEALTH ECONOMIC ANALYSES INTO COVERAGE AND HTA DECISIONS FOR PERSONALIZED MEDICINE DIAGNOSTICS

 

Garfield S, Erickson G, Conner A, Houliston M
GfK Bridgehead, Wayland, MA, USA

PHP21

HOW WILL THE NEW NHS DECENTRALISED REFORMS IMPACT ON ACCESS TO MEDICINES IN ENGLAND?

 

Assimakopoulos M, White R
Access Partnership, London, UK

PHP22

PHARMACOVIGILANCE IN QATAR – A PHARMACIST SURVEY

 

Wilbur K
Qatar University, Doha, Qatar

PHP23

THE EARLY BENEFIT ASSESSMENT OF NEW PHARMACEUTICALS IN GERMANY (“AMNOG”): A STRUCTURED SURVEY ANALYSIS ONE YEAR AFTER ENACTMENT

 

Stoeckel F1, Neubauer AS2
1University of Bayreuth, Bayreuth, Germany, 2IfG Institute for Health Economics, München, Germany

PHP24

SHOULD PHARMACIST REMUNERATION SYSTEMS IN EUROPE BE REFORMED IN ORDER TO INCREASE GENERIC MEDICINE DISPENSING?

 

Dylst P1, Vulto A2, Simoens S3
1KU Leuven, Leuven, Vlaams Brabant, Belgium, 2Erasmus University Medical Center, Hospital Pharmacy, Rotterdam, The Netherlands, 3Katholieke Universiteit Leuven, Leuven, Vlaams Brabant, Belgium

PHP25

WITHDRAWN

 

 

PHP26

REGISTRIES OF MEDICAL DEVICES IN THE EUROPEAN UNION

 

Niederländer CS, Wahlster P, Kriza C, Schaller S, Kolominsky-Rabas P
University of Erlangen-Nuremberg, Erlangen, Germany

PHP27

IMPLEMENTATION OF THE TRANSPARENCY DIRECTIVE IN HUNGARY: SPECIAL FOCUS ON TIME LIMITS FOR PRICING AND REIMBURSEMENT DECISIONS

 

Nagyjanosi L1, Veres I2, Botlik O3, Kalo Z2
1Syreon Research Institute, Budapest, Hungary, 2Eötvös Loránd University, Budapest, Hungary, 3Novartis Hungary, Budapest, Hungary

PHP28

REASONS FOR PROJECT DISCONTINUATION IN THE PHARMACEUTICAL INDUSTRY

 

Puig-Peiró R1, Mestre-Ferrandiz J1, MacDonald F2, Towse A1
1Office of Health Economics, London, UK, 2F. Macdonald Consulting, London, UK

PHP29

INNOVATIVE TECHNOLOGIES: FACTORS INFLUENCING FINANCING DECISIONS IN ITALIAN HOSPITALS

 

Postulka A1, Zaffuto M2, Allibardi S1
1Cepheid Europe, Maurens-Scopont, France, 2Temas-A Quintiles Company, Piacenza, Italy

PHP30

USING NATIONWIDE ADMINISTRATIVE DATA TO EVALUATE GENERIC DRUG PRICING AND PHYSICIAN PRESCRIPTION

 

Shimizu S1, Shimizu T2, Fushimi K3
1Institue for Health Economics and Policy, minato-ku, Tokyo, Japan, 2Institute for Health Economics and Policy, Minato-ku, Tokyo, Japan, 3Tokyo Medical and Dental University Graduate School of Medicine, bunkyo-ku, Tokyo, Japan

PHP31

THE VALUE OF INVESTIGATIONAL MEDICAL PRODUCTS

 

Penzes M1, Kalo Z1, Pozsgay C2, Kalotai Z3
1Eötvös Loránd University, Budapest, Hungary, 2National Institute for Quality- and Organizational Development in Healthcare and Medicines, Budapest, Hungary, 3Novartis Hungary, Budapest, Hungary

PHP32

UNDERSTANDING ACCESSIBILITY FOR NEW MEDICINES ENTERING THE MARKET SINCE 2007 IN PORTUGAL USING SURVIVAL ANALYSIS

 

Silva MJ1, Rabiais S2, Vandewalle B2, Almeida J2, Félix J2
1Exigo Consultores, Alhos Vedros, Lisbon, Portugal, 2Exigo Consultores, Alhos Vedros, Setúbal, Portugal

PHP33

THE USE OF EXTREME VALUE STATISTICS IN ASSESSING LONG DECISION TIMES IN PUBLIC FUNDING OF MEDICINES WITH NEW MOLECULES OR THERAPEUTIC INDICATIONS

 

Vandewalle B1, Silva MJ2, Rabiais S1, Almeida J1, Félix J1
1Exigo Consultores, Alhos Vedros, Setúbal, Portugal, 2Exigo Consultores, Alhos Vedros, Lisbon, Portugal

PHP34

FRANCE MARKET ACCESS: REVIEW OF 2011-2012 ASSESSMENTS BY TRANSPARENCY COMMITTEE

 

Aggarwal S
Novel Health Strategies, Bethesda, MD, USA

PHP35

SYSTEMATIC REVIEW OF KEY ISSUES IN ENDOSCOPE REPROCESSING – GUIDELINE ADHERENCE, HEALTH OUTCOMES AND RESOURCE USE

 

Emmermann A1, Costello S2, Fua S3
1Ethicon Endo-Surgery (Europe) GmbH, Norderstedt, Germany, 2Costello Medical Consulting Ltd., Cambridge, UK, 3Advanced Sterilization Products, Irvine, CA, USA

PHP36

ANALYSIS OF THE REIMBURSEMENT DECISIONS OF THE NATIONAL HEALTH INSURANCE FUND OF HUNGARY (2007-2011)

 

Botlik O, Kalotai Z
Novartis Hungary, Budapest, Hungary

PHP37

NEW CLASSIFICATION OF TRADITIONAL AND INNOVATIVE PHARMACEUTICAL PAYMENT METHODS

 

Hermanowski T1, Czech M2, Chmielewska M3, Kiljan A3, Drozdowska A3, Zawodnik S3, Pashos CL4
1Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland, 2Novo Nordisk Pharma Sp z.o.o., Warsaw, Poland, 3Sopharm Sp. z o.o., Jablonna, Poland, 4United BioSource Corporation, Lexington, MA, USA

PHP38

POINT-OF-CARE DIAGNOSTIC TEST REIMBURSEMENT AND MARKET ACCESS: LESSONS FROM A SURVEY OF GLOBAL HEALTH TECHNOLOGY ASSESSMENTS

 

Spinner DS1, Ransom JF2, Culp JL1, White C3, Doyle JJ4
1Quintiles Consulting, Durham, NC, USA, 2Quintiles Consulting, Hawthorne, NY, USA, 3Quintiles Consulting, Cambridge, MA, USA, 4Quintiles, Hawthorne, NY, USA

PHP39

EXPLANING DIFFERENCES IN EU5 MARKET PENETRATION LEVELS AND RATES OF BIOSIMILARS: THE CASE OF EPOETINE, GRANULOCYTE-COLONY STIMULATING FACTOR, AND GROWTH HORMONES

 

Frenzel A1, Schmidt N2, Grahl J3
1IMS Health, Frankfurt/Main, Germany, 2Johannes Gutenberg-University Mainz, Mainz, Germany, 3Johannes Gutenberg-Universität Mainz, Mainz, Germany

PHP40

AMNOG: PRICING REFORMS IN ACTION

 

Wild L, Forster L
InterPhase P&MA, London, London, UK

PHP41

USE OF SPECIAL PAYMENTS TO ENCOURAGE THE ADOPTION OF INNOVATIVE MEDICAL TECHNOLOGIES IN THE ENGLISH NHS

 

Sorenson C1, Drummond M2, Wilkinson G3
1London School of Economics and European Health Technology Institute for Socio-Economic Research, London, UK, UK, 2University of York, Heslington, York, UK, 3London School of Economics and Political Science, London, UK

PHP42

HEALTH ECONOMICS IN THE CZECH REPUBLIC AND INSURANCE COVERAGE DECISION MAKING IN 2008-2009: A RETROSPECTIVE ANALYSIS

 

Fuksa L1, Heislerova M2, Baloghova K1, Hambalek J3
1General Health Insurance Company of the Czech Republic, Praha, Czech Republic, 2Ministry of Health, Praha, Czech Republic, 3State Institute for Drug Control, Praha, Czech Republic

PHP43

HOW WILL HEALTH CARE REFORM IN RUSSIA AFFECT DRUG PRICING AND REIMBURSEMENT?

 

Wild L, Forster L
InterPhase P&MA, London, London, UK

PHP44

PUBLIC FINANCING OF MEDICINES IN PORTUGAL (2007-2011): ACCESSIBILITY TO MEDICINAL PRODUCTS WITH NEW MOLECULES OR NEW THERAPEUTIC INDICATIONS

 

Félix J1, Vandewalle B1, Silva MJ2, Almeida J1, Rabiais S1
1Exigo Consultores, Alhos Vedros, Setúbal, Portugal, 2Exigo Consultores, Alhos Vedros, Lisbon, Portugal

PHP45

IMPACT OF GENERICS POLICY ON THE GENERIC PENETRATION

 

Ammar H1, Rémuzat C2, Toumi M3
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical France, Paris, France, 3University Claude Bernard Lyon 1, Lyon, France

PHP46

TRENDS IN PREVALENCE OF DRUG USE AMONG DUTCH CHILDREN FROM 2005 UNTIL 2010

 

Joosten SGL1, Houweling LMA2, Penning FJA2
1Utrecht University, Utrecht, The Netherlands, 2PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands

PHP47

DOSE DEPENDENT EVALUATION OF INTESTINAL P-GP ACTIVITY AFTER ONE WEEK ORAL ADMINISTRATION OF BACOPA MONNIERA

 

Singh R1, Panduri J2, Chhonker YS1, Chandasana H1, Shrivastava P1, Kumar D1, Bhatta RS1
1Central Drug Research Institute, Lucknow, Uttar Pradesh, India, 2National Institute of Pharmaceutical Education and Research, Raebareli, India

PHP48

IRRATIONAL USE OF ANTIBIOTICS IN BALOCHISTAN. A WARNING FOR HEALTH CARE SYSTEM

 

Jan SU
University of Balochistan, Quetta, Balochistan, Pakistan

PHP49

IRRATIONAL USE OF ANTIBIOTICS IN CHILDREN BY MEDICAL PRESCRIBERS

 

Jan SU
University of Balochistan, Quetta, Balochistan, Pakistan

PHP50

AMBULATORY PHARMACEUTICAL SPENDING ANALYSIS BASED ON RISK STRATIFICATION IN PATIENTS WITH CHRONIC CONDITIONS

 

Uso Talamantes R1, Trillo Mata JL1, Guadalajara Olmeda N2, Sancho Mestre C2, Vivas Consuelo D2
1Conselleria de Sanidad, Valencia, Spain, Spain, 2Universidad Politecnica de Valencia UPV, Valencia, Spain, Spain

PHP51

PERCEPTION OF PARALLEL TRADE OF PHARMACEUTICALS IN POLAND – RESULTS OF NATIONAL MARKET RESEARCH

 

Baran-Lewandowska I, Hermanowski T
Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland

PHP52

THE CARDIOVASCULAR DRUG UTILISATION IN CROATIA IN THE PERIOD 2007-2010, TRENDS AND PERSPECTIVES

 

Draganic P1, Macolic-Sarinic V2, Zezelic S1
1HALMED, Zagreb, Croatia, 2Halmed, Zagreb, Croatia

PHP53

IDENTIFICATION OF FACTORS AFFECTING THE MEDICINE EXPENDITURES IN PUBLIC HOSPITAL IN MALAYSIA

 

Chan BL1, Ibrahim MIM1, Shafie AA1, Bahri S4
1Universiti Sains Malaysia, Penang, Malaysia, 4Bahagian Perkhidmatan Farmasi, KKM, SELANGOR, Malaysia

PHP54

WITHDRAWN

 

 

PHP55

COMPULSORY LICENSES FOR NON-COMMUNICABLE DISEASES: IMPLICATIONS FOR PHARMACEUTICAL PRICING IN LOW-INCOME COUNTRIES

 

Wasserman M1, Priest VL2
1Double Helix Consulting, London, UK, 2Double Helix Consulting, Asia-Pacific, Singapore, Singapore

HEALTH CARE USE & POLICY STUDIES – Equity and Access

PHP56

HORIZONTAL EQUITY IN PRIMARY HEALTH CARE SERVICES IN TIMES OF ECONOMIC CRISIS IN GREECE: EX ANTE AND EX POST FINDINGS

 

Zavras D, Kyriopoulos II, Pavi E, Kyriopoulos J
National School of Public Health, Athens, Greece

PHP57

EMERGING DRUG REIMBURSEMENT MODELS: LESSONS AND IMPLICATIONS FROM CANCER DRUG ACCESS SCHEMES

 

Aggarwal S
Novel Health Strategies, Bethesda, MD, USA

PHP58

DATA DISCLOSURE AN ONGOING PROCESS TOWARDS MORE TRANSPARENCY

 

Al Rabayah AA
King Hussien Cancer Center, Amman , AL, Jordan

PHP59

EXPLORING THE HEALTH AND LIVING STANDARDS OF THOSE WHO DON'T REPORT THEIR MIGRATION STATUS IN A POPULATION-BASED SURVEY: THE CASE OF CHILE

 

Cabieses B1, Pickett K2, Tunstall H3, Espinoza M2
1Universidad del Desarrollo, Santiago, Yorkshire, Chile, 2University of York, York, Yorkshire, UK, 3University of Edinburgh, Edinburgh, Edinburgh, UK

PHP60

ASSESSMENT OF GEOGRAPHIC PHARMACY ACCESSIBILITY IN QOM (IRAN): A GEOGRAPHIC INFORMATION SYSTEM ANALYSIS

 

Kebriaee Zadeh A1, Hashemi Meshkini A2, Janghorban M3, Keshavarz K2, Nikfar S1
1Tehran University of Medical Sciences, Tehran, Tehran, Iran, 2Tehran University of Medical Sciences, Tehran, Iran, 3Qom Provincial Center, Qom, Qom, Iran

PHP61

EXCESS WEEKEND MORTALITY IN HOSPITALS: A RESULT OF HIGHER SEVERITY OF ILLNESS AT THE TIME OF ADMISSIONS?

 

Paudyal P1, Shepheard-Walwyn T2, Gericke CA1
1Peninsula Medical School/National Institute for Health Research, Plymouth, Devon, UK, 2Lightfoot Solutions UK Limited, Bracknell, Berkshire , UK

PHP62

A NOVEL GLOBAL HEALTH DRUG SUBSIDY AMFM: ASSESSMENT OF DEPLOYMENT IN SOUTHERN GHANA

 

Davies-Teye BBK
Accra Metro Health Directorate, Accra, Greater Accra, Ghana

PHP63

POTENTIAL EFFECTS OF CHANGES IN PRICING REGULATIONS BETWEEN 2004 AND 2011 ON THE TURKISH PHARMACEUTICAL INDUSTRY

 

Memis SA1, Deger C1, Marmarali B1, Parali E1, Sumer F1, Karakeben K1, Kayadibinli M2, Cetinelli ST2
1Bayer Türk, Istanbul, Turkey, 2STATinMED Research, Istanbul, Turkey

PHP64

EVALUATION OF PUBLIC PERCEPTION TOWARDS MEDICINE QUALITY AND PRICES IN AFGHANISTAN

 

Bashaar M, Hassali MAA
Universiti Sains Malaysia, Penang, Malaysia

PHP65

QUALITY OF CARE: REFERENCE AND COUNTER REFERENCE FROM FAMILY PHYSICIANS AND RHEUMATOLOGISTS' PERSPECTIVES– A PILOT STUDY

 

Baumgratz TD1, Battisti R1, Cuziol M1, Janini ACR1, Levy RA2, Abreu MM1
1Universidade Federal de São Carlos, São Carlos, São Paulo, Brazil, 2Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil

PHP66

WITHDRAWN

 

 

HEALTH CARE USE & POLICY STUDIES – Formulary Development

PHP67

REVIEW OF THE CURRENTLY LISTED DRUGS IN SOUTH KOREA

 

Cho JS, Lim MK, Lee JH, Kim JO, Park EY, Sung YN, Kim JY, Yoon SH, Na YW, Lee JH, Lee BI
Health Insurance Review & Assessment Service, Seoul, Secho-Gu, South Korea

HEALTH CARE USE & POLICY STUDIES – Health Care Costs & Management

PHP68

THE EFFECT OF RESETTING THE CLOCK IN HEALTH CARE

 

Gresz M1, Varga S2, Sebestyén A3, Toldi J2, Bogár L2, Molics B2, Boncz I2
1National Institute for Quality- and Organizational Development in Healthcare and Medicines, Budapest, Hungary, 2University of Pécs, Pécs, Hungary, 3South-Trasdanubian Regional Health Insurance Fund Administration, Pécs, Hungary

PHP69

UNITED STATES VALUATION OF CHILD HEALTH OUTCOMES

 

Craig BM1, Brown DS2, Cunningham C3, Greiner W4, Reeve B5
1Moffitt Cancer Center, Tampa, FL, USA, 2Washington University, St. Louis, MO, USA, 3McMaster University, Hamilton, ON, Canada, 4Universität Bielefeld, Bielefeld, Germany, 5University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

PHP70

A SYSTEMATIC REVIEW OF HOSPITAL-AT-HOME CARE: COST SAVINGS ARE OVERESTIMATED

 

Goossens LMA, Vemer P, Rutten-van Mölken MPMH
Erasmus University, Rotterdam, The Netherlands

PHP71

COST EFFECTIVENESS ANALYSIS OF FACILITY AND COMMUNITY BASED PROVISION OF FAMILY PLANNING IN KAMPALA

 

Kaganda PN, Ssengooba F, Baine SO
Makerere University, Kampala, Uganda

PHP72

NEW PRICING POLICIES AFTER INITIATION OF THE HEALTH TRANSFORMATION PROGRAMME IN TURKEY

 

Memis SA1, Deger C1, Marmarali B1, Parali E1, Sumer F1, Karakeben K1, Baser O2
1Bayer Türk, Istanbul, Turkey, 2STATinMED Research/The University of Michigan, Ann Arbor, MI, USA

PHP73

USING DECISION ANALYSIS METHOD TO EVALUATE THE EFFECTIVENESS OF SIMILAR FUNCTION MEDICAL MATERIALS IN HOSPITAL

 

Fang NC1, Yao MJ2, Tseng TY1
1Tunghai University, Taichung City, Taiwan, 2National Chiao Tung University, Hsinchu County, Taiwan

PHP74

COST-OF-ILLNESS OF PATIENT-REPORTED ADVERSE DRUG EVENTS – A POPULATION-BASED SURVEY

 

Gyllensten H1, Rehnberg C2, Jönsson AK3, Petzold M4, Carlsten A1, Andersson Sundell K1
1Nordic School of Public Health NHV, Gothenburg, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3Linköping University, and County Council of Östergötland, Linköping, Sweden, 4University of Gothenburg, Gothenburg, Sweden

PHP75

IS ORPHAN DESIGNATION A DRIVER OF ORPHAN DRUG PRICING?

 

Degrassat-Théas A1, Paubel P2, Parent de Curzon O3, Berard F3, Poisson N3, Le Pen C1, Sinègre M3
1Dauphine University, Paris, France, 2Paris Descartes University, Paris, France, 3General Agency of Equipment and Health Products (AGEPS), AP-HP, Paris, France

PHP76

USE OF ESTIMATES IN THE ECONOMIC MODEL OF THE IMPACT OF NEW HEALTH COVERAGE IN PRIVATE BRAZILIAN MARKET

 

Reis Neto J1, Moralez R2
1CAPESESP/CAPESAUDE, Rio de Janeiro, RJ, Brazil, 2Abbott Brazil, Sao Paulo, Sao Paulo, Brazil

PHP77

HEALTH EXPENDITURE AND DRUG EXPENDITURE - COMPARISON OF TWO WESTERN BALKANS COUNTRIES

 

Krehic J1, Gavrankapetanovic F1, Bolanca S2
1Clinical Center University of Sarajevo, Sarajevo, Bosnia, 2CARPC (Croatian Association of Research Based Pharmaceutical Companies), Zagreb, Croatia

PHP78

SYSTEM-WIDE IMPACT OF PAYMENT SCHEMES FOR INTEGRATED CARE OF CHRONIC DISEASES IN EUROPE: EVIDENCE FROM AN EMPIRICAL ANALYSIS

 

Tsiachristas A, Dikkers C, Boland MRS, Rutten-van Mölken MP
Erasmus University Rotterdam, Rotterdam, The Netherlands

PHP79

STAKEHOLDERS'S VIEWS REGARDING THE IMPACT OF FINANCIAL CRISIS ON THE PHARMACEUTICAL MARKET IN GREECE

 

Tsiantou V, Mylona K, Karampli E, Skroumpelos A, Pavi E, Kyriopoulos J
National School of Public Health, Athens, Greece

PHP80

SYSTEMIC ANTIMICROBIALS CONSUMPTION AND EXPENDITURES IN RUSSIAN MULTI-PROFILE HOSPITALS: THE RESULTS OF MULTICENTER TRIAL

 

Belkova YA1, Ratchina SA1, Kozlov RS1, Mischenko VM1, Kozhuhova LL1, Abubakirova AI2, Berejansky BV3, Eliseeva EV4, Korneva EV5, Palyutin SK6, Portnyagina US7, Pribitkova OV8, Samuilo EK9, Zubareva NA10
1Smolensk State Medical Academy, Smolensk, Russia, 2G.G. Kuvatov Republic Clinical Hospital, Ufa, Russia, 3N.A. Semashko Railway Clinical Hospital, Lublino St., Moscow, Russia, 4Federal State Establishment «DVOMC», Vladivostok, Russia, 5Regional Clinical Hospital, Smolensk, Russia, 6Yaroslavl State Medical Academy, Yaroslavl, Russia, 7Republican Hospital #2, Yakutsk, Russia, 8Clinical Hospital #3, Chelyabinsk, Russia, 9RAS Central Clinical Hospital, Moscow, Russia, 10City Clinical Hospital #6, Perm, Russia

PHP81

MICROECONOMIC SURPLUS OR CONVENIENCE IN HEALTH CARE: APPLIED ECONOMIC THEORY IN HEALTH CARE IN THREE EUROPEAN COUNTRIES

 

Walzer S1, Nuijten M2, Wiesner C3
1Market Access & Pricing Strategy UG (h.b.), Weil am Rhein, Germany, 2Ars Accessus Medica, Amsterdam (Jisp), The Netherlands, 3F. Hoffmann-La Roche Ltd., Basel, Switzerland

PHP82

HEALTH CARE UTILIZATION RESEARCH IN GERMANY: CHARACTERIZATION OF THE NORDBADEN DATABASE

 

Schlander M, Schwarz O
Institute for Innovation & Valuation in Health Care, Wiesbaden, Germany

PHP83

THE OTC POLICY IN EYROPE AND GREECE

 

Milonas A1, Milonas C1, Dokios G2, Kouvelas D3, Maniadakis N4
1National School of Public Health, Athens, Athens, Greece, 2Association of Self Medication in Greece, Athens, Marousi, Greece, 3Aristotle University of Thessaloniki, Thessaloniki, Greece, 4National School of Public Health, Athens, Greece

PHP84

THE ECONOMIC HEALTH VALUE FROM RX TO OTC SWITCH IN GREECE

 

Milonas C1, Milonas A2, Kouvelas D3, Dokios G4, Maniadakis N1
1National School of Public Health, Athens, Greece, 2National School of Public Health, Athens, Athens, Greece, 3Aristotle University of Thessaloniki, Thessaloniki, Greece, 4Association of Self Medication in Greece, Athens, Marousi, Greece

PHP85

THE BENEFITS OF USING OTC: A SYSTEMATIC LITERATURE REVIEW

 

Milonas C1, Milonas A1, Kouvelas D2, Dokios G3, Maniadakis N4
1National School of Public Health, Athens, Athens, Greece, 2Aristotle University of Thessaloniki, Thessaloniki, Greece, 3Association of Self Medication in Greece, Athens, Marousi, Greece, 4National School of Public Health, Athens, Greece

PHP86

COST-EFFECTIVENESS IN HEALTH CARE PROGRAMS: A LITERATURE REVIEW

 

Vanhaute OA1, Annemans L2
1University Hospital Ghent, Belgium, Ghent, Belgium, 2Ghent University & Brussels University, Ghent, Belgium

PHP87

EVALUATION OF REAL LIFE USE OF SUGAMMADEX FOR DECURARIZATION OF NEUROMUSCULAR BLOCKADE IN SURGICAL INTERVENTIONS IN BELGIUM

 

Caekelbergh K, Lamotte M
IMS Health, Vilvoorde, Belgium

PHP88

A REIMBURSEMENT METHOD FOR THE PUBLIC HEALTH CENTERS IN GREECE

 

Skroumpelos A1, Economou N2, Thireos E3, Economidou R4, Pavi E1, Kyriopoulos J1
1National School of Public Health, Athens, Greece, 2Greek NHS, Rhodes, Greece, 3Greek NHS, Athens, Greece, 4Greek NHS, Chalkidiki, Greece

PHP89

MARKET ACCESS OF DRUGS IN FRANCE: EVOLUTION OR REVOLUTION?

 

Rémuzat C1, Toumi M2
1Creativ-Ceutical France, Paris, France, 2University Claude Bernard Lyon 1, Lyon, France

PHP90

JAPANESE PRICING REFORM IN APRIL 2012: TOWARD COST CONTAINMENT

 

Rémuzat C1, Karray SM2, Houas M3, Toumi M4
1Creativ-Ceutical France, Paris, France, 2Creativ-Ceutical, Tunis, Ile de France, Tunisia, 3Creativ-ceutical Paris, Paris, France, 4University Claude Bernard Lyon 1, Lyon, France

PHP91

IS THERE AN OVERUSE OF COMPUTED TOMOGRAPHY (CT) SCANNING OF PATIENTS IN UNITED STATES HOSPITALS? A REVIEW OF THE EVIDENCE

 

Wang Z1, Boswell E1, Kokkotos FK1, Dong X2, Liu Y2, Tong H2, Xiao H2
1Trinity Partners, LLC, Waltham, MA, USA, 2Cornell University, Ithaca, NY, USA

PHP92

STAKEHOLDERS'S VIEWS ON RECENTLY INTRODUCED MEASURES TO PROMOTE GENERICS CONSUMPTION IN GREECE

 

Karampli E, Tsiantou V, Mylona K, Skroumpelos A, Pavi E, Kyriopoulos J
National School of Public Health, Athens, Greece

PHP93

DEVELOPMENT OF BIOSIMILAR MARK IN EU-5 AND USA

 

Ammar H1, Rémuzat C2, Houas M3, Toumi M4
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical France, Paris, France, 3Creativ-ceutical Paris, Paris, France, 4University Claude Bernard Lyon 1, Lyon, France

PHP94

DETERMINANTS OF DRUG THERAPY PROBLEMS AMONG MEDICAID PATIENTS RECEIVING A TELEPHONIC MEDICATION THERAPY MANAGEMENT PROGRAM

 

Snyder ME1, Frail CK1, Jaynes H1, Pater KS2, Zillich AJ1
1Purdue University College of Pharmacy, Indianapolis, IN, USA, 2University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA

PHP95

EFFICIENCY OF GREEK HOSPITALS: BEST PRACTICES OF THREE TOP-PERFORMING HOSPITALS

 

Kaitelidou D1, Kalogeropoulou M1, Pasaloglou S2, Letsios A3, Tsiata K3, Kyriazi M4, Galanakis D4, Maltezaki E5, Asithianakis P5, Liaropoulos L1
1Center for Health Services Management and Evaluatuon, National and Kapodistrian University of Athens, Athens, Greece, 2Novartis Hellas, Metamorfosi, Greece, 3University General Hospital of Patra, Patra, Greece, 4General Hospital of Thessaloniki, Thessaloniki, Greece, 5University General Hospital of Heraklion, Heraklion, Greece

PHP96

EVIDENCE BASED STRUCTURAL REFORM IN THE PROVISION OF HOSPITAL CARE: THE CASE STUDY OF MERGING TWO INSTITUTIONS IN HUNGARY

 

Zemplényi A1, Endrei D1, Boncz I1, Kalo Z2
1University of Pécs, Pécs, Hungary, 2Eötvös Loránd University, Budapest, Hungary

PHP97

THE REGIONAL DISTRIBUTION OF DISABLED PENSIONERS OF HUNGARY

 

Turcsanyi K1, Pakai A1, Szabó J1, Oláh A2, Gombos G1, Gresz M3, Molics B2, Boncz I2
1University of Pécs, Zalaegerszeg, Hungary, 2University of Pécs, Pécs, Hungary, 3National Institute for Quality- and Organizational Development in Healthcare and Medicines, Budapest, Hungary

PHP98

PATIENTS PREFERENCES VERSUS PHYSICIANS JUDGMENT: IS THERE A DIFFERENCE IN HEALTH CARE DECISION MAKING?

 

Mühlbacher AC, Juhnke C
Hochschule Neubrandenburg, Neubrandenburg, Germany

PHP99

IDENTIFYING MAJOR OPERATIONAL CAUSES AND POTENTIAL REMEDIES FOR EMERGENCY DEPARTMENT OVER-CROWDING-CROWDING

 

Schwartz D1, Pliskin JS2, Ronen B3, Goldberg A4
1Ben Gurion University of the Negev, Beer- Sheva, Israel, 2Ben Gurion University of the Negev, Beer-Sheva, Israel, 3Tel Aviv University, Tel Aviv, Israel, 4Ben Gurion University of the Negev, Beer-Sheva, Israel

PHP100

PREVENTION OR TREATMENT? PREFERENCES OF THE AUSTRALIAN PUBLIC FOR HEALTH TECHNOLOGY ASSESSMENT FUNDING CRITERIA

 

Whitty JA1, Ratcliffe J2, Scuffham PA1
1Griffith University, Meadowbrook, Queensland, Australia, 2Flinders University, Daw Park, South Australia, Australia

PHP101

THE IMPLEMENTATION OF DIAGNOSTIC RELATED GROUPS (DRGS) IN GREECE: ONE MOVE FORWARD TO EFFICIENCY

 

Yfantopoulos J1, Panagiotopoulos P2, Letsios A3, Karalis G4, Thiraios E5, Agouras V6, Solakidi A7, Yfantopoulos N8
1National and Kapodistrian University of Athens, Athens, Greece, 2Hippocration Hospital of Athens, Athens, Greece, 3University General Hospital of Patra, Patra, Greece, 4Evangelismos Hospital of Athens, Athens, Greece, 5Ministry of Health, Athens, Greece, 6General Hospital of Lamia, Lamia, Greece, 7University of Peloponnese, Melissia, Greece, 8IPOKE, Halandri, Greece

PHP102

PATIENT SATISFACTION WITH PHARMACIES CONDITION

 

Rasekh H1, Rangchian M2, Mehralian G3, Bagherian SJ1
1Shahid Beheshti Medical University, tehran, Iran, 2Shahid Beheshti Medical University, Tehran, Iran, 3Shahid Beheshti University of Medical Sciences, School of Pharmacy, Tehran, Tehran, Iran

PHP103

CHALLENGES AND FUTURE PROSPECTS OF NURSING WORKFORCE IN GREECE

 

Skroumpelos A1, Gialama F2, Daglas A3, Skoutelis D3, Pavi E1, Kyriopoulos J1
1National School of Public Health, Athens, Greece, 2National School of Public Health, ATHENS, Greece, 3Greek Nurses Association, Athens, Greece

PHP104

A CORRESPONDENCE ANALYSIS OF THE PATIENT'S PERSPECTIVE ON SHARED DECISION MAKING AT THE FAMILY-PHYSICIAN UNIT

 

Cuziol M1, Baumgratz TD1, Battisti R1, Janini ACR1, Levy RA2, Abreu MM1
1Universidade Federal de São Carlos, São Carlos, São Paulo, Brazil, 2Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil

PHP105

IMPACT OF CLINICAL PHARMACY PROGRAM ON PRESCRIPTION ERRORS IN A LEBANESE INSTITUTION: A COST BENEFIT ANALYSIS

 

Nasser S1, Slim M2
1Lebanese American University, Beirut, Blat, Lebanon, 2LebaneseAmerican University, Byblos, Blat, Lebanon

PHP106

IMPACT OF PAYER PERCEPTIONS OF PHARMA COMPANIES ON ACCESS DECISIONS - AN ANALYSIS OF UNPROMPTED EXPRESSIONS IN PAYER INTERVIEWS

 

Ruppert A, Petrie N, King Z, Plata A, Rao N
IMS Consulting Group, Cambridge, UK

PHP107

EXPERTS' VIEWS ON THE INTRODUCTION OF A MONOPSONY IN HEALTH CARE SERVICES IN GREECE

 

Skroumpelos A, Zavras D, Pavi E, Kyriopoulos J
National School of Public Health, Athens, Greece

PHP108

EARLY ACCESS PROGRAMMES (EAPS): REVIEW OF NON- EUROPEAN SYSTEM

 

Urbinati D1, Toumi M2
1Creativ-Ceutical, Luxembourg, Luxembourg, 2University Claude Bernard Lyon 1, Lyon, France

PHP109

PRACTICE CHANGE IN ITALIAN COMMUNITY PHARMACY: AN ANALYSIS OF MANAGERIAL IMPLICATION

 

Vagnoni E1, Heidari M2
1University of Ferrara, Ferrara, Italy, 2University of Ferrara, Ferrara, Ferrara, Italy

PHP110

GAINING REIMBURSEMENT OF ORPHAN PRODUCTS IN EUROPE: CHALLENGES DUE TO WIDE VARIATIONS IN EVIDENCE REQUIREMENTS AND PROCESSES

 

Heron L1, Laurenson S1, Costello J1, Anderl C2, Knospe J2
1Adelphi Values, Bollington, Cheshire, UK, 2Santen GmbH, Germering, Germany

PHP111

FACTORS PREDICTING REIMBURSEMENT DECISIONS ON ORPHAN DRUGS IN EIGHT COUNTRIES

 

Kanters T, Redekop W, Hakkaart L
Erasmus University Rotterdam, Rotterdam, The Netherlands

PHP112

ESTIMATING THE PROBABILITY OF A FAVORABLE ASSESSMENT OF CLINICAL BENEFITS FOR A NEW DRUG IN GERMANY USING AN MCDA APPROACH

 

Williams P1, Mauskopf J1, Kilburg A2, Lebiecki J2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI Health Solutions, Manchester, UK

PHP113

THE IMPORTANCE OF ECONOMIC EVALUATIONS IN THE ASSESSMENT OF REIMBURSEMENT APPLICAITIONS

 

Jacobi M1, Orrskog S2, Medin E2
1Karolinska Institutet, Stockholm, Sweden, 2Heron Evidence Development AB, Stockholm, Sweden

PHP114

REVIEW OF COST EFFECTIVENESS STUDIES OF HIGH BUDGET IMPACT DRUGS (2007-2012)

 

Kockaya G1, Demir M2, Uresin AY2
1Covidien, Ankara, Turkey, 2Istanbul Medical Faculty, Istanbul, Turkey

PHP115

THE SHARP DECREASE OF DRUG'S ACCESS TO REIMBURSEMENT IN FRANCE IN 2011

 

Hounkanlin H, Troubat A, Morlet Vigier D
IMS Health, Puteaux, France

PHP116

ORPHAN DRUG PRICING AND ACCESS – CURRENT SITUATION AND FUTURE TRENDS IN EU

 

Jeffery M, White R
Access Partnership, London, UK

PHP117

SMC DECISIONS: ARE THEY GETTING TOUGHER?

 

Morawski J
Quintiles Consulting, Hoofddorp, The Netherlands

PHP118

ESTIMATING THE PROBABILITY OF A RECOMMENDATION FOR REIMBURSEMENT FOR A NEW DRUG IN THE UK USING AN MCDA APPROACH

 

Williams P1, Mauskopf JA1, Kilburg A2, Lebiecki J2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI Health Solutions, Manchester, UK

PHP119

VALUE AND THE MULTIPLE CRITERIA USED IN OECD COUNTRIES' MEDICINE REIMBURSEMENT DECISION-MAKING PROCESSES USING HEALTH ECONOMIC EVIDENCE

 

Bending MW, Smith TA
MAPI Consultancy, London, UK

PHP120

NEW PRICING DYNAMICS IN BIG FIVE EU: CASE STUDY OF BIOSIMILAR GM-CSF PRODUCTS

 

Aggarwal S
Novel Health Strategies, Bethesda, MD, USA

PHP121

DRUG REIMBURSEMENT MAINTENANCE: A FRENCH CHALLENGE IN 2011

 

Hounkanlin H, Troubat A, Morlet Vigier D
IMS Health, Puteaux, France

PHP122

THE USE OF QUANTITATIVE AND QUALITATIVE CRITERIA FOR MAKING DRUG FUNDING DECISIONS

 

Rübesam T1, Jain M2
1University of Gloucestershire, Cheltenham, UK, 2BioMarin Europe Limited, London, UK

PHP123

IMPORTANCE OF HEALTH-RELATED QUALITY OF LIFE AS AN ENDPOINT IN BENEFIT ASSESSMENT ACCORDING TO THE GERMAN AMNOG

 

Koester C1, Kossmann B1, Boehm K1, Wasem J2, Aidelsburger P1
1CAREM GmbH, Sauerlach, Bavaria, Germany, 2University Duisburg-Essen, Essen, Germany

PHP124

COMPARISON OF HTA DOSSIER REQUIREMENTS ACROSS EUROPE

 

Casamayor M, Van Engen A
Quintiles Global Consulting, Hoofddorp, Noord-Holland, The Netherlands

PHP125

AN EARLY ASSESSMENT OF THE GERMAN FEDERAL JOINT COMMISSION RESOLUTIONS OF ADDITIONAL CLINICAL BENEFIT

 

McBride D1, Kilburg A1, Mauskopf J2
1RTI Health Solutions, Manchester, UK, 2RTI Health Solutions, Research Triangle Park, NC, USA

PHP126

FROM INNOVATION TO MARKET ACCESS: REIMBURSEMENT STRATEGIES OF MEDICAL INDUSTRY IN DUTCH HEALTH CARE

 

Den Breejen E1, Putters K2, Philipszoon FA3
1PhilMed Healthcare Marketing / Erasmus University Rotterdam, Riel, The Netherlands, 2Erasmus University Rotterdam, Rotterdam, The Netherlands, 3PhilMed Healthcare Marketing, Riel, The Netherlands

PHP127

REIMBURSEMENT OF ORPHAN DRUGS: WHAT IS THE DIFFERENCE?

 

Mueller E1, Schmidt E1, Ehreth J2
1Analytica LA-SER International Inc., Loerrach, Germany, 2LA-SER Europe, Paris, France

PHP128

AMNOG IN YEAR 2: INSIGHTS FROM EARLY BENEFIT ASSESSMENTS IN GERMANY

 

Schmidt E, Mueller E
Analytica LA-SER International Inc., Loerrach, Germany

PHP129

WITHDRAWN

 

 

PHP130

GUIDELINES WITHOUT GUIDANCE: THE CASE OF EPIDEMIOLOGICAL DATA BEYOND CLINICAL TRIALS

 

Sandmann FG1, Herrmann KH1, Zhou M1, Gerber A2, Lhachimi SK1
1Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany, 2Institute of Quality and Efficiency in Health Care (IQWiG), Köln, Germany

PHP131

ENSURING THAT PHASE III PROGRAMS ARE DESIGNED TO MEET THE EVOLVING HTA REQUIREMENTS ACROSS THE EU5

 

Lucas F1, Secker-Johnson R2
1Pope Woodhead and Associates, St. Ives, UK, 2Cambridge University, Cambridge, UK

PHP132

TIME TO MARKET ACCESS FOR INNOVATIVE DRUGS IN THE UK, FRANCE, AND BELGIUM

 

Maervoet J1, Toumi M2
1Deloitte, Diegem, Belgium, 2University Claude Bernard Lyon 1, Lyon, France

PHP133

MARKET ACCESS OF DRUGS IN FRANCE AND MEDICO-ECONOMIC ASSESSMENT

 

Rémuzat C1, Toumi M2, Aballea S3
1Creativ-Ceutical France, Paris, France, 2University Claude Bernard Lyon 1, Lyon, France, 3Creativ-Ceutical, Paris, France

PHP134

BIOSIMILAR PRICING: PAST, PRESENT AND FUTURE

 

Wild L, Forster L
InterPhase P&MA, London, London, UK

PHP135

STAKEHOLDERS'S VIEWS OF THE SOCIAL INSURANCE REFORM IN GREECE

 

Mylona K, Skroumpelos A, Tsiantou V, Karampli E, Pavi E, Kyriopoulos J
National School of Public Health, Athens, Greece

PHP136

GENERIC PRICE LINKAGE AS A POLICY CHOICE: REVIEW OF RECENT DEVELOPMENTS

 

Izmirlieva M1, Ando G2
1IHS, London, UK, UK, 2IHS Global Insight, London, UK

PHP137

CHANGES IN THE MEDICINES PRICING AND REIMBURSEMENT APPROACH IN BULGARIA

 

Nikolov I1, Marcheva M1, Marinov D2, Georgieva S3, Petrova G3
1GlaxoSmithKline, Sofia, Bulgaria, 2Pharmacy Doverie, Sofia, Sofia, Bulgaria, 3Medical University, Faculty of Pharmacy, Sofia, Bulgaria

PHP138

IMPACT OF VALUE BASED PRICING ON FUTURE OF PATIENT ACCESS SCHEMES IN THE UNITED KINGDOM

 

Izmirlieva M1, Walker S1, Marinoni G2, Ando G3
1IHS, London, UK, UK, 2IHS, London, UK, 3IHS Global Insight, London, UK

HEALTH CARE USE & POLICY STUDIES – Health Care Research & Education

PHP139

WHICH CRITERIA ARE CONSIDERED IN HEALTH CARE DECISIONS? INSIGHTS FROM AN INTERNATIONAL SURVEY OF POLICY AND CLINICAL DECISION MAKERS

 

Tanios N1, Wagner M2, Tony M1, Baltussen R3, van Til JA4, Rindress D2, Kind P5, Goetghebeur MM2
1University of Montreal, Montreal, QC, Canada, 2BioMedCom Consultants Inc., Dorval, QC, Canada, 3Radboud University, Nijmegen, Gelderland, The Netherlands, 4University of Twente, Enschede, Overijssel, The Netherlands, 5University of York, York, UK

PHP140

CHALLENGES IN THE DATA COLLECTION REGARDING PATIENT POPULATION AND TREATMENT COSTS FOR NON-DRUG INTERVENTIONS USING THE EXAMPLE OF MORBUS DUPUYTREN

 

Kürschner N, Schiffner-Rohe J
Pfizer Deutschland GmbH, Berlin, Germany

PHP141

EFFECTS OF CHANGING HEALTH POLICY ON PHARMACOECONOMICS AND HEALTH OUTCOME STUDIES IN TURKEY

 

Kockaya G1, Daylan Kockaya P2, Ergin Oguzhan G1
1Health Economics and Policy Association, Ankara, Turkey, 2Sile Government Hospital, Istanbul, Turkey

PHP142

DRUG SHORTAGES AROUND THE WORLD AND THE UNDERLYING REASONS

 

Holtorf AP1, Rinde H2, Maniadakis N3
1Health Outcomes Strategies, GmbH, Basel, Switzerland, 2BioBridge Strategies, Binningen, BL, Switzerland, 3National School of Public Health, Athens, Greece

PHP143

EXPLORATORY TEST OF STAKEHOLDER THEORY IN THE IMPLEMENTATION PROCESS OF IT-INNOVATIONS IN HOSPITAL CARE

 

Lambooij MS1, Hummel M2
1National Institute of Public Health and the Environment, Bilthoven, The Netherlands, 2University of Twente, Enschede, The Netherlands

PHP144

ECONOMIC EFFECT OF CLINICAL TRIALS FOR TURKEY

 

Kockaya G1, Demir M2, Uresin AY2
1Health Economics and Policy Association, Ankara, Turkey, 2Istanbul Medical Faculty, Istanbul, Turkey

PHP145

USING AN EVIDENCE DATABASE OF PREVIOUS NICE HTA DECISIONS TO MAXIMISE RE-REVIEW STRATEGY

 

Goad C1, Sainz G1, Cevro E2, Philips Z1
1Abacus International, Manchester, UK, 2Amgen Ltd., Uxbridge, UK

PHP146

PHARMACOECONOMIC EDUCATION FOR PHARMACY STUDENTS IN THE RUSSIAN FEDERATION

 

Makhinova T1, Makhinova EN2, Rascati KL1
1The University of Texas at Austin, Austin, TX, USA, 2Voronezh State University, Voronezh, Russia

PHP147

EARLY ACCESS PROGRAMMES (EAPS): REVIEW OF THE EUROPEAN SYSTEM

 

Urbinati D1, Toumi M2
1Creativ-Ceutical, Luxembourg, Luxembourg, 2University Claude Bernard Lyon 1, Lyon, France

HEALTH CARE USE & POLICY STUDIES – Health Technology Assessment Programs

PHP148

EARLY BENEFIT ASSESSMENT (EBA) IN GERMANY: DIFFERENCES BETWEEN PHARMACEUTICAL COMPANIES' CLAIMS AND IQWIG BENEFIT ASSESSMENTS

 

Ruof J1, Dintsios CM2, Schwartz F3
1Roche Pharma, Grenzach-Wyhlen, Germany, 2German Association of Research-based Pharmaceutical Companies (vfa), Berlin, Germany, 3Hannover Medical School, Hannover, Germany

PHP149

HEALTH TECHNOLOGY ASSESSMENT EVIDENCE CRITERIA: WHAT TYPES OF EVIDENCE SHOULD BE PRESENTED FOR PRODUCTS USED TO SCREEN FOR DISEASE IN THE UNITED STATES?

 

McGee NM
Lash Group, San Bruno, CA, USA

PHP150

SEARCHING FOR A THRESHOLD IN HUNGARY

 

Borsi A
National Institute for Quality- and Organizational Development in Healthcare and Medicines, Budapest, Hungary

PHP151

THE INFLUENCE OF PATIENT COMPLIANCE ARGUMENTS IN NICE TECHNOLOGY APPRAISALS

 

Brown AP1, Chauhan D2, Guarnieri C1, Philips Z1
1Abacus International, Manchester, UK, 2Takeda, London, UK

PHP152

THE EARLY BENEFIT ASSESSMENT OF DRUGS THAT ARE LAUNCHED BEFORE 2011

 

Weber B
Pfizer, Berlin, Germany

PHP153

SUPPORTING PAYERS WITH COLLABORATIVE HTA TOOLS IN MAKING EVIDENCE-BASED DECISIONS: THE UNITED STATES EXPERIENCE AND INTERNATIONAL NEEDS IN EUROPE AND GLOBALLY

 

Brixner D1, Lising A2, Gothe H3, Häussler B4, Dragovich C5
1University of Utah, College of Pharmacy, Salt Lake City, UT, USA, 2Dymaxium Healthcare Innovations, Toronto, ON, ON, Canada, 3UMIT, Hall, Hall, Austria, 4IGES Institut GmbH, Berlin, Germany, 5Academy of Managed Care Pharmacy, Alexandria, VA, USA

PHP154

A STUDY COMPARING THE DIFFERENT PROCEESES FOR PATIENT INPUT IN SIX DIFFERENT EUROPEAN HTA SYSTEMS

 

Hicks N1, Toumi M2
1Commutateur, paris , France, 2University Claude Bernard Lyon 1, Lyon, France

PHP155

A COMPARATIVE STUDY OF THE MULTIPLE TECHNOLOGY ASSESSMENT PROCESS IN THE UNITED KINGDOM AND AUSTRALIA

 

Lu CY1, Ward R2
1Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA, 2University of New South Wales, Sydney, NSW, Australia

PHP156

AMNOG – SUMMARY OF OUTCOMES OF EARLY BENEFIT ASSESSMENT AND REIMBURSEMENT NEGOTIATION FOR NEW DRUGS IN GERMANY

 

Claus V1, Freyer D1, Kotowa W2, Mathes J2
1Novartis Pharma GmbH, Nuremberg, Germany, 2IGES Institut GmbH, Nuremberg, Germany

PHP157

TO WHAT EXTENT DOES THE FEDERAL JOINT COMMITTEE FOLLOWS THE EVIDENCE BASED RECOMMENDATIONS BY IQWIG

 

Weber B1, Schmitter S2, Schiffner-Rohe J2
1Pfizer, Berlin, Germany, 2Pfizer Deutschland GmbH, Berlin, Germany

PHP158

CROSS-FUNTIONAL CHALLENGES IN THE PREPARATION OF A BENEFIT DOSSIER

 

Schmitter S1, Hartge M2, Zibell G2, Schiffner-Rohe J1
1Pfizer Deutschland GmbH, Berlin, Germany, 2Pfizer Pharma GmbH, Berlin, Germany

PHP159

PROPOSED AND ACTUAL BUREAUCRATIC BURDEN OF HTA SUBMISSIONS TO THE INDUSTRY- CASE STUDIES FROM GERMANY AND UNITED KINGDOM

 

Schweikert B1, Jonsson L2
1OptumInsight, Munich, Germany, 2OptumInsight, Stockholm, Sweden

PHP160

BENEFITS OF PROBABALISTIC SENSITIVITY ANALYSIS

 

Adalsteinsson JE1, Toumi M2
1Novo Nordisk A/S, Copenhagen, Denmark, 2University Claude Bernard Lyon 1, Lyon, France

PHP161

INTEGRATION OF VALUE OF INFORMATION INTO THE DECISION MAKING PROCESS IN IRELAND

 

McCullagh LM1, Walsh C2, Barry M3
1National Centre for Pharmacoeconomics, Dublin, Ireland, 2Trinity College Dublin, Dublin, Ireland, 3St. James's Hospital, Dublin, Ireland, Ireland

PHP162

REVIEW OF NICE'S TECHNOLOGY APPRAISAL RECOMMENDATIONS

 

Rinaldi F, George E, Longson C
National Institute for Health and Clinical Excellence, Holborn, London, UK

PHP163

ASSESSING THE QUALITY OF MANUFACTURERS' SEARCHES IN NICE SINGLE TECHNOLOGY APPRAISALS BY EVIDENCE REVIEW GROUPS

 

Wong R, Paisley S, Carroll C
The University of Sheffield, Sheffield, UK

PHP164

PAYER INFORMATION REQUIREMENTS FOR RELATIVE EFFECTIVENESS ASSESSMENT VARY ACROSS MARKETS AND CREATE DISCREPENCIES IN PATIENT ACCESS TO MEDICINES

 

Marinoni G1, Lockwood C1, Honoré AC1, Rodrigues T1, Izmirlieva M1, Walker S1, Ando G2
1IHS, London, UK, 2IHS Global Insight, London, UK

PHP165

EXPLORING THE ROLE OF THE COMMITTEE IN THE NICE APPRAISAL PROCESS: HOW CONSISTENT ARE DECISIONS ACROSS COMMITTEES?

 

McCann E, Plested M
HERON, Luton, UK

PHP166

WITHDRAWN

 

 

PHP167

THE ROLE OF DECISION-ANALYTIC MODELING IN GERMAN HEALTH TECHNOLOGY ASSESSMENTS

 

Kuhlmann A1, Braun S2, Schulenburg JM1
1Leibniz Universität Hannover, Hannover, Germany, 2HERESCON GmbH, Hannover, Germany

PHP168

CALCULATED FORECAST FOR TECHNICAL OBSOLESCENCE IN COMPUTERISED TOMOGRAPHY EQUIPMENT

 

Reyes-Santias F1, Vivas-Consuelo D2, Ramos M2
1Universidad de Vigo, Vigo, Spain, 2Universidad Politecnica de Valencia, Valencia, Spain

PHP169

COMPARING THE HUNGARIAN METHODOLOGICAL GUIDELINE FOR CONDUCTING ECONOMIC EVALUATION OF HEALTH CARE INTERVENTION WITH EUROPEAN GUIDELINES

 

Huszti Z, Nagy BZ
National Institute for Quality- and Organizational Development in Healthcare and Medicines, Budapest, Hungary

PHP170

THE SWISS HEALTH TECHNOLOGY ASSESSMENT (HTA) CONSENSUS: GUIDING PRINCIPLES

 

Schlander M1, Affolter C2, Sandmeier H3, Cueni T4, Gyger P5, Hebborn A6, Herren D7, Kaufmann S2, Kraft E8, Suter P9
1Institute for Innovation & Valuation in Health Care, Wiesbaden, Germany, 2Santésuisse, Solothurn, Switzerland, 3Interpharma, Basel, Switzerland, 4Chair of the EFPIA Economic and Social Policy Committee, Basel, Switzerland, 5Helsana Versicherungen AG, Dübendorf, Switzerland, 6F. Hoffmann-La Roche AG, Basel, Switzerland, 7Schulthess Klinik, Zürich, Switzerland, 8FMH Verbindung der Schweizer Ärztinnen und Ärzte, Bern, Switzerland, 9Swiss Academy of the Medical Sciences (SAMW), Basel, Switzerland

PHP171

HTA PRINCIPLES INCLUSION IN NEW EUROPEAN UNION MEMBER STATES

 

Tomek D1, Visnansky M2, Marusakova E3
1Pharmaceutical Faculty at Comenius University, Bratislava, Slovak Republic, 2SLOVAHTA, Bratislava, Slovak Republic, 3GlaxoSmithKline Slovakia, Bratislava, Slovak Republic

HEALTH CARE USE & POLICY STUDIES – Patient Registries & Post-Marketing Studies

PHP172

CHALLENGES IN DEVELOPING A NEW SYSTEM FOR REGISTRATION OF PATIENT REGISTRIES

 

Gliklich R1, Levy D1, Campion DM1, Leavy MB1, Karl J1, Berliner E2, Khurana L1, Hossfeld W1
1Outcome, A Quintiles Company, Cambridge, MA, USA, 2Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA

HEALTH CARE USE & POLICY STUDIES – Population Health

PHP173

DISENTANGLING THE RELATIONSHIP BETWEEN DISABILITY, SOCIOECONOMIC STATUS AND SOCIAL CAPITAL IN CHILE: A POPULATION-BASED STUDY

 

Zitko P1, Cabieses B2, Pickett K3, Espinoza M3
1Hospital Barros Luco, Santiago, Chile, 2Universidad del Desarrollo, Santiago, Yorkshire, Chile, 3University of York, York, Yorkshire, UK

PHP174

PHYSICAL ACTIVITY MATTERS: THE ASSOCIATIONS BETWEEN BODY MASS INDEX, PHYSICAL ACTIVITY AND HEALTH-REALTED QUALITY-OF-LIFE TRAJECTORIES OVER 10 YEARS

 

Feeny DH1, Garner R2, Bernier J2, Thompson A2, McFarland BH3, Huguet N4, Kaplan MS4, Ross NA5, Blanchard C6
1University of Alberta, Portland, OR, USA, 2Statistics Canada, Ottawa, ON, Canada, 3Oregon Health & Science University, Portland, OR, USA, 4Portland State University, Portland, OR, USA, 5McGill University, Montreal, QC, Canada, 6Dalhousie University, Halifax, NS, Canada

PHP175

ECONOMIC PERFORMANCE AND EPIDEMIOLOGICAL TRANSITION IN MEXICO

 

Reyes-Lopez A
Mexican Children Hospital, Mexico City, Mexico

PHP176

SOCIOECONOMIC INEQUALITIES CONCERNING THE SELF-RATED HEALTH STATUS IN GREECE: A COMPARATIVE ANALYSIS OF POST-CRISIS EFFECTS

 

Kyriopoulos II, Zavras D, Pavi E, Kyriopoulos J
National School of Public Health, Athens, Greece

HEALTH CARE USE & POLICY STUDIES – Prescribing Behavior & Treatment Guidelines

PHP177

CHARACTERISTICS OF PATIENTS NOT CONSUMING PHARMACOLOGICAL RESOURCES DUE TO A LACK OF DRUG PRESCRIPTION DURING THEIR HOSPITAL ADMISSION

 

Salas E1, Grau S2, Luque S3, Mateu-de Antonio J3, Ferrández O3, Urbina O3, Mojal S4, Marin-Casino M3
1Pharmacy Department, Hospital del Mar. Barcelona, Barcelona, Spain, 2Hospital del Mar (IMIM), Barcelona, Spain, 3Hospital del Mar, Barcelona, Spain, 4Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain

PHP178

VALIDITY OF SELF-REPORTED HEALTH CARE UTILIZATION: TOWARDS A RESEARCH CONSENSUS

 

Chernyak N1, Jülich F1, Droste S1, Icks A1, Dintsios CM2
1Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, 2German Association of Research-based Pharmaceutical Companies (vfa), Berlin, Germany

PHP179

EVALUATION OF PRESCRIBING PRACTICES OF CLINICIANS IN GOVERNMENT TEACHING HOSPITAL IN PAKISTAN

 

Akhtar M, Ahmad M, Ahmad I
The Islamia University of Bahawalpur, Bahawalpur, Punjab, Pakistan

HEALTH CARE USE & POLICY STUDIES – Quality of Care

PHP180

MULTIPLE CORRESPONDENCE ANALYSIS TO UNDERSTAND THE ROLE OF MULTIPROFESSIONAL TEAM FOR SHARED DECISION MAKING TO IMPLEMENTATION IN CLINICAL PRACTICE

 

Janini ACR1, Cuziol M1, Battisti R1, Baumgratz TD1, Levy RA2, Abreu MM1
1Universidade Federal de São Carlos, São Carlos, São Paulo, Brazil, 2Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil

HEALTH CARE USE & POLICY STUDIES – Regulation of Health Care Sector

PHP181

COSTS/QALY THRESHOLD IN NEW LEGISLATION AND ITS IMPACT ON ACCESS TO INNOVATIVE MEDICINES IN SLOVAKIA

 

Tomek D1, Psenkova M2, Tomekova K3, Mackovicova S4
1Slovak Medical University, Bratislava, Slovak Republic, 2Pharm-In, Bratislava, Slovak Republic, 3Slovak Society for Pharmacoeconomics, Bratislava, Slovak Republic, 4Pharm-In, spol. s r.o., Bratislava, Slovak Republic

PHP182

CONCORDANCE OF PRO LABELING CLAIMS BETWEEN THE FDA AND EMA

 

Gnanasakthy A1, Doward L2, Clark M3, Mordin M3, DeMuro C4
1Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 2RTI Health Solutions, Manchester, Manchester, UK, 3RTI Health Solutions, Ann Arbor, MI, USA, 4RTI Health Solutions, Research Triangle Park, NC, USA

PHP183

THE ROCKY ROAD TO MARKET EQUILIBRIUM – PRICE REGULATION AND ENTRY LIBERALIZATION IN PORTUGUESE RETAIL PHARMACY

 

Barros PP1, Martins B2, Moura A2
1Nova School of Business and Economics, Lisbon, Portugal, 2Nova School of Business and Economics, Lisboa, Lisboa, Portugal

PHP184

CHANGING MARGINS IN PHARMACEUTICAL DISTRIBUTION: WHO BENEFITS FROM THE NEW SLICING OF THE PIE?

 

Barros PP1, Martins B2, Moura A2
1Nova School of Business and Economics, Lisbon, Portugal, 2Nova School of Business and Economics, Lisboa, Lisboa, Portugal

PHP185

THE PHARMACISTS' AND PATIENTS' SIDE OF POLICY MEASURES IN PHARMACEUTICAL MARKETS: THE EFFECTS OF CHANGING PHARMACY MARGINS

 

Barros PP1, Martins B2, Moura A2, Teixeira I3, Costa S4, Queirós S5
1Nova School of Business and Economics, Lisbon, Portugal, 2Nova School of Business and Economics, Lisboa, Lisboa, Portugal, 3Centre of Health Research & Evaluation (CEFAR), National Association of Pharmacies (ANF), Lisbon, Portugal, 4CEFAR (Centre for Health Research & Evaluation), Lisboa, Portugal, 5National Association of Pharmacies (ANF), Lisboa, Portugal

HEALTH CARE USE & POLICY STUDIES – Risk Sharing/Performance-Based Agreements

PHP186

TRENDS IN THE USE OF HEALTH ECONOMIC DATA TO INFORM GLOBAL MARKET ACCESS DECISIONS: PRELIMINARY RESULTS FROM AN ONLINE SURVEY

 

Szende A1, Azzabi Zouraq I2, Ackerman SJ3
1Covance, Leeds, West Yorkshire, UK, 2Covance, Geneva, Switzerland, 3Covance Market Access Services, Inc., San Diego, CA, USA

PHP187

PHARMACOVIGILANCE AND THE CASE STUDY OF VIOXX

 

Krancberg AN, Chmielewska M, Hermanowski TR
Medical University of Warsaw, Warsaw, Poland

PHP188

FUNDING THE UNFUNDABLE: THE AUSTRALIAN APPROACH FOR SPECIALTY PHARMACEUTICALS

 

Lu CY
Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA

PHP189

TRENDS IN THE USE OF INNOVATIVE CONTRACTING MODELS BETWEEN THE PHARMACEUTICAL INDUSTRY AND PAYERS IN EUROPE

 

Shekarriz S1, Hoday K2, Zöllner YF3
1Hamburg University of Applied Sciences, Hamburg, Germany, 2Executive Insight AG, Zurich, Switzerland, 3Hamburg University of Applied Sciences, Hamburg, Germany

PHP190

GLOBAL PHARMACEUTICAL RISK-SHARING AGREEMENT TRENDS IN 2011 AND 2012: SLOWING DOWN?

 

Ando G1, Izmirlieva M2, Honoré AC3
1IHS Global Insight, London, UK, 2IHS, London, UK, UK, 3IHS, Zurich, Switzerland

PHP191

IMPACT OF A FINANCIAL RISK-SHARING SCHEME ON BUDGET-IMPACT ESTIMATIONS: A GAME-THEORETIC APPROACH

 

Hammerman A, Segev E, Gavious A, Greenberg D
Ben Gurion University of the Negev, Beer-Sheva, Israel

PHP192

RECENT GLOBAL INSIGHTS INTO RISK SHARING AGREEMENTS: A COMPARATIVE ANALYSIS

 

Bruinsma IJ, Morawski J, Nijhuis T
Quintiles Consulting, Hoofddorp, The Netherlands

HEALTH CARE USE & POLICY STUDIES – Conceptual Papers

PHP193

PAEDIATRIC USE MARKETING AUTHORISATION (PUMA): THE CHALLENGES OF COST-EFFECTIVENESS MODELLING WHERE LIMITED CLINICAL TRIAL INFORMATION IS AVAILABLE

 

Gladwell D1, Lee D1, Tate E2, Batty A1, Brereton NJ1
1BresMed, Sheffield, UK, 2Hayward Medical Communications, Newmarket, Suffolk, UK

PHP194

WHY DO PATIENTS ENGAGE IN MEDICAL TOURISM?

 

Carrera P
University of Twente, Enschede, The Netherlands

PHP195

ADOPTION OF NEW TECHNOLOGIES IN TWENTY ESTABLISHED AND EMERGING MARKETS

 

Hertz D, Marcarelli AD, Patel L, Garfield S
GfK Bridgehead, Wayland, MA, USA

PHP196

STAKEHOLDER INVOLVEMENT IN HEALTH TECHNOLOGY ASSESSMENT (HTA) OF NOVEL MEDICAL DEVICES

 

Hidefjall P
KTH Royal School of Technology, Huddinge, Huddinge, Sweden

PHP197

OPPORTUNITIES AND LIMITATIONS OF SUSTAINABILITY INDICES IN SATISFYING THE NEEDS OF HEALTH TECHNOLOGY PURCHASERS SEEKING OBJECTIVE AND UNBIASED INDICATORS OF ENVIRONMENTAL AND SOCIETAL IMPACTS

 

Wright AJ, Froehlich HJ
PHMR Associates, London, UK

PHP198

FROM SCIENCE TO SERVICE: THE ONTARIO PATIENT REPORTED OUTCOMES OF SYMPTOMS AND TOXICITY (ON-PROST) RESEARCH UNIT

 

Howell D, Perez Cosio A, Liu G, Rodin G, Hope A
University Health Network, Toronto, ON, Canada

PHP199

THE IMPACT OF THE GERMAN PHARMACEUTICAL MARKET REORGANISATION ACT (AMNOG) ON THE GERMAN REFERENCE PRICE MARKET – TRENDS TWO YEARS AFTER THE INTRODUCTION OF THE AMNOG

 

Eheberg D1, Batscheider A1, Lebioda A1, Plantör S1, Fricke FU2
1IMS Health GmbH & Co. OHG, Munich, Germany, 2IMS Health GmbH & Co. OHG, Nuremberg, Germany

PHP200

EFFECTIVE DEMAND FOR A HEALTH LITERATE HEALTH CARE SYSTEM - EVIDENCE FROM IRISH SURVEY DATA

 

Coughlan D
National University of Ireland, Galway, Galway, Ireland

PHP201

CAN RISK MANAGEMENT PLANS (RMP) CONTRIBUTE TO HEALTH TECHNOLOGY ASSESSMENT (HTA) AND KNOWLEDGE OF SAFETY IN EVERYDAY MEDICAL PRACTICE?

 

Prieto L1, Spooner A2, Hidalgo-Simon A1, Rubino A1, Kurz X1, Arlett P1
1European Medicines Agency, London, UK, 2Irish Medicines Board, Dublin, Ireland

PHP202

BRIDGING THE GAP BETWEEN INSTITUTIONAL LEVELS USING SYSTEMS ANALYSIS

 

Lim ME1, Bowen J2, Goeree R1, Tarride JE1
1McMaster University, Hamilton, ON, Canada, 2PATH Research Institute, McMaster University, Hamilton, ON, Canada

PHP203

HOW TO OPTIMISE CHANCES FOR SUCCESSFUL AMNOG ASSESSMENTS – BEST PRACTICE APPROACH FOR GERMAN MARKET ACCESS

 

Bonduelle D, Plantoer S
IMS GmbH & Co. OHG, Munich, Bavaria, Germany

PHP204

APPROPRIATE METHODS FOR ECONOMIC EVALUATION OF PROGRAMMES WITH COSTS AND EFFECTS EXTENDING ACROSS SECTORS

 

Walker S1, Griffin S2, Claxton K3, Palmer S2, Sculpher MJ4
1University of York, York, UK, 2University of York, York, North Yorkshire, UK, 3University of York, Heslington, York, UK, 4University of York, Heslington, UK

PHP205

PRIMARY CARE TRANSFORMATION AS A SOLUTION TO THE EPIDEMIC OF CHRONIC DISEASES

 

Carrera P
University of Twente, Enschede, The Netherlands

PHP206

ASSESSING THE VALUE OF ACCESS TO INDIVIDUAL PATIENT DATA FOR REIMBURSEMENT DECISIONS

 

Manca A
University of York, Heslington, York, UK

SESSION I – MONDAY, 5 NOVEMBER
SET-UP: Monday, 5 November 2012, 8:30 – 8:45
POSTER DISPLAY HOURS: Monday, 5 November 2012, 8:45 - 14:15
POSTER AUTHOR DISCUSSION HOUR: Monday, 5 November 2012, 13:15 – 14:15
DISMANTLE: Monday, 5 November 2012, 14:15

GASTROINTESTINAL DISORDERS – Clinical Outcomes Studies

PGI1

THE EFFECTIVENESS AND TOLERABILITY OF COMBINED TREATMENT WITH PEGINTERFERON ALPHA-2A OR ALPHA-2B AND RIBAVIRIN IN THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C: RESULTS BASED ON THE NATIONWIDE HEPATITIS REGISTRY IN JAPAN

 

Shimbo T, Miyaki K, Song Y, Masaki N, Study Group Developing Nationwide Database of Hepatitis Japan .
National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan

PGI2

INFLIXIMAB REDUCES THE RISK OF SURGICAL INTERVENTIONS AND HOSPITALIZATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

 

Costa J1, Alarcão J1, Caldeira D2, Borges M1, Vaz Carneiro A1
1Center for Evidence Based Medicine, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, 2Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Lisbon, Portugal

PGI3

TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 1 IN POLAND – REAL-LIFE DATA

 

Kaczor MP1, Pawlik D2, Wójcik R2, Rolka M2, Maniszewska-Weyher I3, Tronczynski K3
1Jagiellonian University Medical College, Kraków, Poland, 2Aestimo s.c., Kraków, Poland, 3Janssen-Cilag Polska, Warsaw, Poland

PGI4

EVALUATION OF THE EFFICACY AND INCONTINENCE RATE OF BIOMATERIALS IN COMPARISON TO CONSERVATIVE AND OTHER INTERVENTIONAL THERAPIES IN TREATMENT OF PERIANAL FISTULA. A META-ANALYSIS

 

Mirfazaelian H1, Nikfar S2, Derakhshani S3, Abdollahi M1
1Tehran University of Medical Sciences, Tehran, Iran, 2Tehran University of Medical Sciences, Tehran, Tehran, Iran, 3Parsian Hospital, Tehran, Iran

PGI5

EFFECTIVENESS AND SAFETY OF ANTACIDS IN PREGNANT WOMEN SUFFERING FROM GERD/HYPERACIDITY SYMPTOMS

 

Donde S1, Kumari B2, Usha G3
1Pfizer India, Mumbai, India, 2VIMS Hospital, Kadavanthara, Ernakulam, India, 3Usha Hospital, TamilNadu, Kanyakumari Dist, India

GASTROINTESTINAL DISORDERS – Cost Studies

PGI6

A BUDGET IMPACT ANALYSIS TO ESTIMATE THE ECONOMIC IMPACT OF LACTEST FOR THE DIAGNOSIS OF HYPOLACTASIA IN SPAIN

 

Darba J1, Kaskens L2, Ramírez de Arellano A3
1Universitat de Barcelona, Barcelona, Spain, 2BCN Health, Barcelona, Spain, 3Ferrer Grupo, Barcelona, Spain

PGI7

ADHERENCE TO 5-AMINOSALICYLIC ACID (5-ASA) THERAPIES IN ULCERATIVE COLITIS (UC): A UNITED KINGDOM (UK) BUDGET IMPACT ANALYSIS

 

Szende A1, Neves D2, McDermott JD2, Yen L3
1Covance, Leeds, West Yorkshire, UK, 2Covance Market Access Services, Inc., Gaithersburg, MD, USA, 3Shire Development LLC, Wayne, PA, USA

PGI8

SECOND AND THIRD GENERATION FVIII TREATMENT RESOURCES CONSUMPTION BREAK-EVEN POINT: THE PASS STUDY RESULTS

 

Gringeri A1, Cortesi PA2, Fusco F3, Cristiani M4, Mantovani LG5, Turchetti G3
1Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico/University of Milan, Milano, Italy, 2University of Milano - Bicocca, Monza, Italy, 3Scuola Superiore Sant'Anna Univesity, Pisa, Italy, 4Charta fondation, milano, Italy, 5Federico II University of Naples, Naples, Italy

PGI9

PHARMACOECONOMIC EVALUATION OF ANTYHELICOBACTER THERAPY OF ULCERS DUODENUM IN UKRAINE

 

Iakovlieva L1, Gerasymova O1, Mishchenko O1, Bezditko N2, Kyrychenko O3
1National University of Pharmacy, Kharkiv, Ukraine, 2National University of Pharmacy, Ukraine, Kharkiv, Ukraine, 3National University of Pharmacy, Kharkiv , Ukraine

PGI10

WITHDRAWN

 

 

PGI11

WITHDRAWN

 

 

PGI12

COST OF DISEASE RELATED MALNUTRITION IN CROATIA – A HIDDEN COST IN THE HEALTH CARE CLOSET WANTS OUT

 

Benkovic V1, Kolcic I2, Ivicevic Uhernik I1, Krznaric Z3, Vranesic Bender D3, Stevanovic R1
1Croatian Society for Pharmacoeconomics and Health Economics, Zagreb, Croatia, 2Faculty of Medicine, University of Split, Split, Croatia, 3Centre for Clinical Nutrition, University Hospital Centre Zagreb, Croatia, Zagreb, Croatia

PGI13

ECONOMIC BURDEN AND TREATMENT PATTERNS OF ADULT PATIENTS WITH CHRONIC CONSTIPATION IDENTIFIED THROUGH RETROSPECTIVE DATABASE RESEARCH

 

Löfroth E1, Bruce Wirta S1, Hodgkins P2, Bloomfield E3, Kerstens R4, Joseph A5
1IMS Health, Stockholm, Sweden, 2Shire Pharmaceuticals LLC, Wayne, PA, USA, 3IMS Health, London, UK, 4Shire-Movetis NV, Turnhout, Belgium, 5Shire Switzerland, Eysins, Switzerland

PGI14

CHARACTERISTICS OF DIVERTICULITIS-RELATED EMERGENCY DEPARTMENT VISITS IN THE UNITED STATES

 

Candrilli SD1, Davis KL1, Yen L2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Shire Development LLC, Wayne, PA, USA

PGI15

COST-EFFECTIVENESS ANALYSIS OF LACTEST, A NEW DIAGNOSTIC DRUG TEST FOR HYPOLACTASIA IN SPAIN

 

Darba J1, Kaskens L2, Ramírez de Arellano A3
1Universitat de Barcelona, Barcelona, Spain, 2BCN Health, Barcelona, Spain, 3Ferrer Grupo, Barcelona, Spain

PGI16

COST EFFECTIVENESS OF BOCEPREVIR PLUS PEGINTERFERON ALPHA AND RIBAVIRIN VERSUS TELAPREVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN IN THE TREATMENT OF CHRONIC HEPATITIS C (CHC) IN PREVIOUSLY UNTREATED GENOTYPE I PATIENTS

 

Fonseca M1, Garran V2, Araujo GT3
1Federal University of São Paulo / Axia.Bio Consulting, São Paulo, Brazil, 2MSD, São Paulo, Brazil, 3Axia.Bio Consulting, Sao Paulo, Sao Paulo, Brazil

PGI17

COST-EFFECTIVENESS OF TELAPREVIR WITH PEGINTERFERON AND RIBAVIRIN FOR TREATMENT-NAIVE PATIENTS CHRONICALLY INFECTED WITH HCV OF GENOTYPE 1 IN JAPAN

 

Ishida H1, Terai S2, Sakaida I2, Inoue Y2
1Yamaguchi University Hospital, Ube, Yamaguchi, Japan, 2Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan

PGI18

COST-EFFECTIVENESS OF BOCEPREVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA AND RIBAVIRIN FOR THE TREATMENT OF GENOTYPE 1 CHRONIC HEPATITIS C: SUBMISSION TO THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE)

 

Humphreys SC1, Elbasha EH2, Ferrante SA2, Lion M1, O'Regan C1
1Merck Sharp & Dohme Ltd., Hoddesdon, UK, 2Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA

PGI19

COSTS AND EFFECTS OF DUAL THERAPY WITH PEGYLATED INTERFERON AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C IN GERMANY

 

Berg T1, Buggisch P2, Mauss S3, Wedemeyer H4, Benter U5, Decker-Burgard S6
1Universitätsklinikum Leipzig, Leipzig, Germany, 2Ifi-Institut Hamburg, Hamburg, Germany, 3Center for HIV and Hepatogastroenterology, Duesseldorf, Germany, 4Medizinische Hochschule Hannover, Hannover, Germany, 5INC Research LLC, Munich, Germany, 6Janssen-Cilag GmbH, Neuss, Germany

PGI20

COST-EFFECTIVENESS OF ADALIMUMAB FOR TREATMENT OF CROHN'S DISEASE IN GERMANY

 

Yang M1, Yang M2, Skup M2, Zhou ZY1, Hengst N3, Wolff M3, Mulani PM2, Chao J2
1Analysis Group, Inc., Boston, MA, USA, 2Abbott Laboratories, Abbott Park, IL, USA, 3Abbott GmbH & Co. KG, Ludwigshafen, Germany

PGI21

COST EFFECTIVENESS OF THE COMBINATION OF BOCEPREVIR PLUS PEGINTERFERON ALPHA AND RIBAVIRIN VERSUS TELAPREVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN IN THE RETREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE I INFECTION

 

Fonseca M1, Garran V2, Araujo GT3
1Federal University of São Paulo / Axia.Bio Consulting, São Paulo, Brazil, 2MSD, São Paulo, Brazil, 3Axia.Bio Consulting, Sao Paulo, Sao Paulo, Brazil

PGI22

COST-EFFECTIVENESS ANALYSIS OF DEXLANSOPRAZOLE FOR THE TREATMENT OF EROSIVE ESOPHAGITIS COMPARED TO CONVENTIONAL PROTON PUMP INHIBITORS

 

Valencia-Romero A1, Gay-Molina JG2, Chiu-Ugalde J3, Figueroa-Rodriguez A3, López-Alvarenga JC4, Sánchez-Kobashi R2, Vargas JA3
1Hospital de Alta Especialidad PEMEX Sur, Mexico City, Mexico, 2Tecnología e Informática para la Salud, S.A. de C.V., Mexico City, Mexico, 3Nycomed: A Takeda Company, Naucalpan, Edo.
Mexico, Mexico, 4Hospital General de México O.D., Mexico City, Mexico

PGI23

COST-EFFECTIVENESS OF EPISODIC OR MAINTENANCE INFLIXIMAB VERSUS STANDARD TREATMENT IN AN INCIDENCE COHORT OF CROHN'S DISEASE PATIENTS WITH 10-YEARS FOLLOW-UP

 

Odes S1, Greenberg D2, Vardi H2, Friger M2, Stockbrugger R3, Munkholm P4
1Soroka Medical Center, Beer-Sheva, Israel, 2Ben Gurion University of the Negev, Beer-Sheva, Israel, 3University Hospital Maastricht, Maastricht, The Netherlands, 4Herlev Hospital and University of Copenhagen, Copenhagen, Denmark

PGI24

COST-EFFECTIVENESS ANALYSIS OF 48-WEEK PEGINTERFERON ALPHA-2A UNDER RGT STRATEGY VERSUS 3 YEARS ENTECAVIR FOR THE TREATMENT OF HBEAG-POSITIVE CHRONIC HEPATITIS B IN CHINA

 

Zhang W1, Zhuang H2, Ren H3, Dou X4, Chen W5
1Huashan Hospital Medical Center of Fudan University, Shanghai, China, 2Peking University Health Science Center, Beijing, China, 3Second Affiliated Hospital of Chongqing University of Medical Science, Chongqing, China, 4Shengjing Hospital of China Medical University, Shenyang, China, 5Fudan University, Shanghai, China

PGI25

COST-UTILITY ANALYSIS OF TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALPHA AND RIBAVIRIN IN PREVIOUSLY TREATED PATIENTS WITH CHRONIC HEPATITIS C

 

Lukac M1, Bielik J2, Holoman J3, Tomek D4, Suvadova A5, Foltanova T6, Foltan V7
1Slovak Medical University, Bratislava, Slovak Republic, 2Trencin University, Trencin, Slovak Republic, 3National Reference Center for Managment and Therapy of Chronic Hepatitis, Bratislava, Slovak Republic, 4Pharmaceutical Faculty at Comenius University, Bratislava, Slovak Republic, 5Janssen, Bratislava, Slovak Republic, 6Faculty of Pharmacy, Bratislava, Slovak Republic, 7Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic

PGI26

WITHIN-TRIAL ANALYSIS TO ESTIMATE THE ECONOMICALLY JUSTIFIABLE PRICE OF LINACLOTIDE IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN THE UNITED KINGDOM

 

McDonell A1, Barzey V1, Kotchie R1, Mungapen L1, Prior M2, Fortea J2
1IMS, London, UK, 2Almirall, Barcelona, Spain

PGI27

IMPACT OF LINACLOTIDE TREATMENT ON WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN ADULTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION

 

Buono JL1, Tourkodimitris S1, Sarocco P2, Baird MJ2, Johnston JM2, Carson R1
1Forest Research Institute, Jersey City, NJ, USA, 2Ironwood Pharmaceuticals, Cambridge, MA, USA

PGI28

GASTROESOPHAGEAL REFLUX DISEASE: IMPACT ON WORK PRODUCTIVITY AND DAILY LIFE ACTIVITIES OF DAYTIME WORKERS. A FRENCH CROSS SECTIONAL STUDY (ACTA)

 

Bruley des Varannes S1, Ducrotte P2, Vallot T3, Maurel F4, Bardoulat I5, Garofano A6, Carrois F7, Ricci L7
1University of Nantes, Nantes, France, 2Hôpital Charles Nicolle, Rouen Cedex, France, 3Clinique Claude Bernard, Ermont, France, 4IMS Health, 92807 Puteaux Cedex, France, 5IMS Health, Puteaux Cedex, France, 6IMS Health, Puteaux, France, 7Janssen, Issy-les-Moulineaux, France

PGI29

COST OF CHRONIC HEPATITIS C (HCV) IN POLAND – HEALTH CARE PROFESSIONALS SURVEY

 

Kaczor MP1, Pawlik D2, Wójcik R2, Tronczynski K3, Kiwala C3
1Jagiellonian University Medical College, Kraków, Poland, 2Aestimo s.c., Kraków, Poland, 3Janssen-Cilag Polska, Warsaw, Poland

PGI30

ASSESSMENT OF PRACTICE PATTERNS AND TREATMENT-FAILURE COSTS AMONG PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION: FINDINGS FROM A PHYSICIAN SURVEY STUDY

 

Menzin J1, Huang H1, Carson RT2, Taylor D3, Sarocco P3, Blum SI2
1Boston Health Economics, Inc., Waltham, MA, USA, 2Forest Research Institute, Jersey City, NJ, USA, 3Ironwood Pharmaceuticals, Inc., Cambridge, MA, USA

GASTROINTESTINAL DISORDERS – Patient-Reported Outcomes & Patient Preference Studies

PGI31

IMPACT OF TREATMENT RESPONSE ON HEALTH UTILITIES AND WORK PRODUCTIVITY AMONG PATIENTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION: POOLED RESULTS FROM PHASE III CLINICAL TRIALS

 

Huang H1, Taylor D2, Carson RT3, Sarocco P2, Menzin J1
1Boston Health Economics, Inc., Waltham, MA, USA, 2Ironwood Pharmaceuticals, Inc., Cambridge, MA, USA, 3Forest Research Institute, Jersey City, NJ, USA

PGI32

NEW ANTIVIRAL DRUGS FOR HEPATITIS C IN ITALY: WILL IT BE A TREASURE HUNT?

 

Gardini I1, Fontana R1, Fumagalli M1, Conforti M1, Lanati EP2
1EPAC - Hepatic Patient Association, Vimercate, MB, Italy, 2MA Provider, Milano, Italy, Italy

PGI33

ASSESSING GAS-RELATED SYMPTOMS AND THEIR ASSOCIATED IMPACT ON THE DAILY LIFE OF THE GENERAL POPULATION AND IRRITABLE BOWEL SYNDROME PATIENTS: INTERNATIONAL DEVELOPMENT OF A QUESTIONNAIRE – QUALITATIVE STEPS

 

Tugaut B1, Guyonnet D2, Marrel A1, Arbuckle R3, Azpiroz F4, Whorwell P5, Chassany O6
1MAPI Consultancy, Lyon, France, 2Danone Research, Palaiseau, France, 3Adelphi Values, Bollington, Cheshire, UK, 4Hospital General Vall d'Hebron, Barcelona, Spain, 5Wythenshawe Hospital, Manchester, UK, 6Assistance Publique-Hopitaux de Paris & Denis-Diderot University, Paris, France

PGI34

A PATIENT-REPORTED OUTCOME MODEL FOR CROHN'S DISEASE

 

Wilburn J1, McKenna S1, Twiss J1, Ben-L'amri M1, Kemp K2, Campbell S2
1Galen Research Ltd, Manchester, Gtr Manchester, UK, 2Manchester Royal Infirmary, Manchester, Gtr Manchester, UK

PGI35

HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HAEMOPHILIA AND INHIBITORS ON PROPHYLAXIS WITH ANTI-INHIBITOR COMPLEX CONCENTRATE: RESULTS FROM THE PRO-FEIBA STUDY

 

Gringeri A1, Leissinger C2, Cortesi PA3, Fusco F4, Riva S5, Mantovani LG6
1Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico/University of Milan, Milan, Italy, Italy, 2Tulane University, New Orleans, LA, USA;, New Orleans, LA, USA, 3University of Milano - Bicocca, Monza, Italy, 4Scuola Superiore Sant'Anna Univesity, Pisa, Italy, 5Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico/University of Milan, Milan, New Orleans, USA, 6Federico II University of Naples, Naples, Italy

PGI36

RELATIONSHIP BETWEEN CLINICAL SEVERITY AND HEALTH RELATED QUALITY OF LIFE IN CHRONIC LIVER DISEASES

 

Scalone L1, Cortesi PA1, Ciampichini R2, Okolicsanyi S3, Rota M3, Ciaccio A3, Ideo G4, Colledan M5, Belli LS6, Cesana G1, Mantovani LG7, Strazzabosco M3
1University of Milano - Bicocca, Monza, Italy, 2Charta Foundation, Milan, Italy, 3University of Milano - Bicocca, Monza (MB), Italy, 4Fondazione FADE, Milano, Italy, 5Ospedali Riuniti, Bergamo, Italy, 6Niguarda Hospital, Milan, Italy, 7Federico II University of Naples, Naples , Italy

PGI37

FINALISATION AND PSYCHOMETRIC VALIDATION OF A NEW QUESTIONNAIRE MEASURING PATIENT SATISFACTION WITH ANTI-TNF TREATMENTS IN SEVERE CROHN'S DISEASE

 

Arnould B1, Fofana F1, Gilet H1, Colombel JF2, Faure P3, Hagège H4, Nachury M2, Nahon S5, Tucat G6, Vandromme L7, Clerson P8, d'Hondt O8, Cazala Telinge I9, Hauville C9, Thibout E10
1MAPI Consultancy, Lyon, France, 2Hôpital Claude Huriez, Lille, France, 3Clinique Saint-Jean du Languedoc, Toulouse, France, 4Centre Hospitalier intercommunal, Créteil, France, 5Centre Hospitalier intercommunal, Montfermeil , France, 6Private doctor, Paris, France, 7Private doctor, Reims, France, 8Orgametrie, Roubaix, France, 9Abbott Laboratories, Rungis, France, 10Abbott France, Rungis, France

GASTROINTESTINAL DISORDERS – Health Care Use & Policy Studies

PGI38

THE CONSUMPTION OF PROTON-PUMP INHIBITORS IN SLOVAKIA

 

Gatialová K1, Bellova K2, Foltan V1, Majtás J2
1Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic, 2Comenius University, Bratislava, Slovak Republic

PGI39

BUDEGT IMPACT ANALYSIS OF HCV THERAPY COST AFTER BOCEPREVIR ADDITION TO STANDARD THERAPEUTIC REGIME

 

Manova M1, Savova A1, Stoimenova A1, Petrova G2
1Medical University Sofia, Faculty of Pharmacy, Sofia, Bulgaria, 2Medical University, Faculty of Pharmacy, Sofia, Bulgaria

PGI40

PHYSICIAN-INITIATED TREATMENT PATTERNS OF ULCERATIVE COLITIS (UC) PATIENTS IN THE UNITED KINGDOM (UK): A REVIEW OF CHART-ABSTRACTED DATA

 

Yen L1, Katic BJ2
1Shire Development LLC, Wayne, PA, USA, 2Shire, Wayne, PA, USA

SESSION I – MONDAY, 5 NOVEMBER
SET-UP: Monday, 5 November 2012, 8:30 – 8:45
POSTER DISPLAY HOURS: Monday, 5 November 2012, 8:45 - 14:15
POSTER AUTHOR DISCUSSION HOUR: Monday, 5 November 2012, 13:15 – 14:15
DISMANTLE: Monday, 5 November 2012, 14:15

MENTAL HEALTH – Clinical Outcomes Studies

PMH1

ANTAGONISTIC DRUG PRESCRIBING: CHOLINESTERASE INHIBITORS AND ANTICHOLINERGICS

 

Huisman L, Dijkstra H, Vegter S
University of Groningen, Groningen, The Netherlands

PMH2

INTERIM RESULTS FROM THE "AUTOR" STUDY, A EUROPEAN OBSERVATIONAL STUDY IN PEDIATRIC PATIENTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER: PATIENT CHARACTERISTICS AND 1-YEAR COSTS

 

Haynes V1, Quail D2, Lorenzo M2, Deix C3, Anand H2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Eli Lilly and Company, Surrey, UK, 3Eli Lilly and Company, Vienna, Austria

PMH3

WITHDRAWN

 

 

PMH4

MIRROR IMAGE STUDIES OF RISPERIDONE LONG-ACTING INJECTION FOR CHRONIC SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER

 

Einarson TR1, Jensen R2, Hemels M3
1University of Toronto, Toronto, ON, Canada, 2Janssen EMEA, Birkerød, Denmark, 3Janssen Cilag, Birkerød, Denmark

PMH5

SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF TREATMENTS USED FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

 

Roskell NS1, Setyawan J2, Zimovetz E1, Hodgkins P2
1RTI Health Solutions, Manchester, UK, 2Shire Pharmaceuticals LLC, Wayne, PA, USA

PMH6

EVOLUTION OF ANTIDEPRESSANT EFFICACY OVER TIME: ILLUSTRATION WITH ESCITALOPRAM

 

Llorca PM1, Lançon C2, Brignone M3, Rive B4, Painchault C5, Bent-Ennakhil N6, François C7
1Centre Hospitalier Univ, Clermont-Ferrand , France, 2Hopital Sainte-Marguerite CHU, Marseille , France, 3Lundbeck S.A.S., Issy-les-Moulineaux cedex, France, 4Lundbeck S.A.S., Issy-Les Moulineaux, France, 5Keyrus Biopharma, Levallois-Perret, France, 6Lundbeck S.A.S., Issy-les-Moulineaux, France, 7Lundbeck S.A.S., Issy-les-Moulineaux , France

PMH7

WITHDRAWN

 

 

PMH8

COST OF METHYLPHENIDATE AND ATOMOXETINE PRESCRIBING TO CHILDREN AND ADULTS IN SOUTH AFRICA

 

Truter I
Nelson Mandela Metropolitan University, Port Elizabeth, Eastern Cape, South Africa

PMH9

ANTIDEPRESSANT PRESCRIPTION PATTERNS AMONG PATIENTS WITH MAJOR DEPRESSION BASED ON CLAIMS DATABASE IN JAPAN

 

Onishi Y1, Hinotsu S1, Furukawa TA2, Kawakami K1
1Kyoto University, Kyoto, Japan, 2Kyoto University, kyoto, Kyoto-fu, Japan

PMH10

PATIENT PERSISTENCE WITH BUPRENORHINE/NALOXONE FILM AND TABLET FORMULATIONS IN THE TREATMENT OF OPIOID DEPENDENCE IN THE UNITED STATES: RESULTS FROM A LARGE PRIVATELY INSURED RETROSPECTIVE DATABASE

 

Clay E1, Ruby J2, Aballea S1, Zah V3
1Creativ-Ceutical, Paris, France, 2Reckitt Benckiser Pharmaceuticals, Inc./NA, Richmond, VA, USA, 3Health Economics Consultant, Belgrade, Serbia and Montenegro

MENTAL HEALTH – Cost Studies

PMH11

COSTS OF CHILDREN WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) BEING COMPLIANT OR NON-COMPLIANT TO PHARMACOLOGICAL TREATMENT: RESULTS FROM A DUTCH OBSERVATIONAL STUDY

 

Van Der Kolk A1, Bouwmans C2, Schawo S2, Buitelaar JK3, van der Gaag RJ4, Van Agthoven M5, Hakkaart-van Roijen L6
1Janssen-Cilag BV The Netherlands, Tilburg, The Netherlands, 2Erasmus University Rotterdam, Rotterdam, The Netherlands, 3Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands, 4Karakter Universitair Centrum, Nijmegen, The Netherlands, 5Janssen-Cilag BV, Tilburg, The Netherlands, 6Erasmus Universiteit Rotterdam, Rotterdam, The Netherlands

PMH12

ARE DISEASE RELATED COSTS OF CARE FOR MAJOR DEPRESSION IN GERMANY OVERESTIMATED? – USING CLAIMS DATA TO ASSESS THE INFLUENCE OF DISEASE SEVERITY AND COMORBIDITY

 

Wagner CJ1, Gerber A2, Lhachimi SK1
1Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany, 2Institute of Quality and Efficiency in Health Care (IQWiG), Köln, Germany

PMH13

LONGITUDINAL ANALYSIS OF PATIENT LEVEL HEALTH CARE COSTS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH DULOXETINE

 

Cui Z1, Faries DE1, Shen W1, Able SL1, Novick D2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Eli Lilly and Company, Windlesham, Surrey, UK

PMH14

REAL-LIFE COST-ANALYSES OF PATIENTS WITH GENERALIZED ANXIETY DISORDER IN DENMARK

 

Sætterstrøm B1, Poulsen PB2, Olsen J1, Strand M2, Hetmar O3
1University of Southern Denmark, Odense, Denmark, 2Pfizer Denmark, Ballerup, Denmark, 3Mental Health Centre Sct Hans, Roskilde, Denmark

PMH15

AN ECONOMIC SYSTEMATIC REVIEW ON BIPOLAR DISORDER IN CHILDREN AND ADOLESCENTS: COST-EFFECTIVENESS OF TREATMENTS, COSTS OF CARE AND QUALITY OF LIFE

 

Lister S1, Pitsi D1, Mehta R2, Kusel J3
1Bristol-Myers Squibb UK, Uxbridge, UK, 2Otsuka Pharmaceuticals UK, Uxbridge, UK, 3Costello Medical Consulting Ltd., Cambridge, UK

PMH16

ANALYSIS OF THE ECONOMIC BURDEN AND COST STRUCTURE OF SCHIZOPHRENIA IN GERMANY USING OBSERVATIONAL SICKNESS FUND DATA

 

Frey S1, Linder R2, Stargardt T1
1University of Hamburg, Hamburg, Germany, 2Scientific Institute of TK for Benefit and Efficiency in Health Care, Hamburg, Germany

PMH17

ECONOMIC BURDEN IN SCHIZOPHRENIA: A LITERATURE REVIEW

 

Millier A1, Shupo F2, Chauhan D3, Toumi M4
1Creativ-Ceutical, Paris, France, 2Creativ-Ceutical, London, UK, 3Takeda, London, UK, 4University Claude Bernard Lyon 1, Lyon, France

PMH18

TREATMENT PATTERNS AND COSTS IN PATIENTS WITH SCHIZOPHRENIA IN GERMANY

 

Zeidler J1, Heres S2, Mahlich JC3, Greiner W4
1Leibniz University Hannover, Hannover, Germany, 2Technical University of Munich, Munich, Germany, 3Janssen-Cilag GmbH, Neuss, Nordrhein-Westfa, Germany, 4Universität Bielefeld, Bielefeld, Germany

PMH19

WITHDRAWN

 

 

PMH20

METABOLIC CONSEQUENCES AND COST-EFFECTIVENESS OF ASENAPINE IN THE TREATMENT OF BIPOLAR DISORDER

 

Selya-Hammer C1, Gauthier A1, Millar HL2, Barnett AH3, Marre C4
1Amaris, London, UK, 2Mental Health Directorate, Dundee, UK, 3Birmingham Heartlands Hospital, Birmingham, UK, 4Lundbeck S.A.S., Issy les Moulineaux, France

PMH21

COST-EFFECTIVENESS OF INTRAMUSCULAR ZIPRASIDONE FOR THE TREATMENT OF ACUTE AGITATION ASSOCIATED TO SCHIZOPHRENIA IN MEXICO

 

Galindo-Suárez RM1, Peniche-Otero G2, Herrera-Rojas J2, Baeza-Cruz G2, Nenclares-Portocarrero A3, Muciño-Ortega E1
1Pfizer S.A. de C.V., Mexico City, Mexico, 2Customized Premium Products S.A. de C.V., Mexico City, Mexico, 3Pfizer S.A. de C.V., Mexico City, Distrito Federal, Mexico

PMH22

COST-UTILITY ANALYSIS OF DEPOT ATYPICAL ANTIPSYCHOTICS FOR CHRONIC SCHIZOPHRENIA IN CROATIA

 

Jukic V1, Jakovljevic M2, Filipcic I2, Herceg M3, Silic A4, Tomljanovic T5, Jensen R6
1Psychiatry hospital ‘Vrapce', Zagreb, Croatia, 2University Hospital Zagreb, Zagreb, Croatia, 3Vrapce Psychiatric Hospital, Zagreb, Croatia, 4Psychiatric Hospital Sveti Ivan, Zagreb, Croatia, 5Janssen div Johnson & Johnson, Zagreb, Croatia, 6Janssen Cilag, Birkerød, Denmark

PMH23

A COST-EFFECTIVENESS ANALYSIS OF THE LONG-ACTING ANTISPYCHOTIC DRUGS PALIPERIDONE PALMITATE, OLANZAPINE PAMOATE AND RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA IN FINLAND

 

Einarson TR1, Pudas H2, Zilbershtein R3, Jensen R4, Nielsen AT5, Piwko C3, Hemels M6, Vincente C7
1University of Toronto, Toronto, ON, Canada, 2Janssen, Espoo, , Finland, 3Pivina Consulting Inc., Thornhill, ON, Canada, 4Janssen EMEA, Birkerød, Denmark, 5University of Copenhagen, Frederiksberg C, Denmark, 6Janssen Cilag, Birkerød, Denmark, 7PIVINA, Mississauga, ON, Canada

PMH24

COST OF LONG-ACTING RISPERIDONE INJECTION VERSUS LONG-ACTING PALIPERIDONE PALMITATE IN PATIENTS WITH SCHIZOPHRENIA IN RUSSIA

 

Omelyanovsky V1, Avxentyeva M1, Ivakhnenko O1, Khailov P2, Tsfasman FM1, Krysanov I1, Zorin N1
1Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Russian National Research Medical University, Moscow, Russia, 2Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Russian National Research Medical University, Moscow, Russia

PMH25

AN ASSESSEMENT OF THE COST-EFFECTIVENESS OF ESCITALOPRAM VERSUS MULTIPLE COMPARATORS AS FIRST LINE ANTIDEPRESSANT IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD) IN BELGIUM

 

Druais S1, Gauthier A1, Demyttenaere K2, Brignone M3, De Pauw A4, Defraigne G4, Annemans L5
1Amaris, London, UK, 2University Psychiatric Center KuLeuven, Leuven, Belgium, 3Lundbeck S.A.S., Issy-les-Moulineaux, France, 4s.a. Lundbeck n.v., Brussels, Belgium, 5Ghent University & Brussels University, Ghent, Belgium

PMH26

COST-EFFECTIVENESS OF ATYPICAL VERSUS TYPICAL ANTIPSYCHOTICS IN PATIENTS WITH SCHIZOPHRENIA IN RUSSIA

 

Omelyanovsky V1, Avxentyeva M1, Ivakhnenko O1, Khailov P2, Krysanov I1, Tsfasman FM1
1Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Russian National Research Medical University, Moscow, Russia, 2Research Center for Clinical and Economic Evaluation and Pharmacoeconomics, Russian National Research Medical University, Moscow, Russia

PMH27

COST-EFFECTIVENESS ANALYSIS OF DEPRESSION IN ITALY

 

Katz P1, Mencacci C2, Di Sciascio G3, Ripellino C1, Heiman F1
1CSD Medical Research S.r.l., Milan, Italy, 2Fatebenefratelli Hospital, Milan, Italy, 3Azienda Ospedaliero Universitaria , Bari, Italy

PMH28

USING COST-EFFECTIVENESS ANALYSIS TO DEFINE THE OPTIMAL GROUP OF PATIENTS TO BENEFIT FROM RISPERIDONE LONG-ACTING INJECTABLE

 

Valencia-Mendoza A, Hernández-Garduño A
Janssen de Mexico, Mexico, D.F., Mexico

PMH29

COST EFFECTIVENESS OF QUETIAPINE EXTENDED RELEASE COMPARED WITH QUETIAPINE IMMEDIATE RELEASE IN SCHIZOPHRENIC PATIENTS IN MEXICO

 

Pozo Urquizo L1, Pizarro M2, Soto H3, Gonzalez A4, Salazar A4, Polanco AC5
1Iteliness S A de CV, Mexico City, Mexico, 2Hospital Infantil de Mexico Federico Gomez, Mexico City, Mexico, 3Iteliness Consulting, México DF, Distrito Federal, Mexico, 4Iteliness S A de CV, Mexico, DF, Mexico, 5AstraZeneca, México, D. F., México, D. F., Mexico

PMH30

COST-MINIMIZATION-ANALYSIS OF PALIPERIDONE PALMITATE IN THE TREATMENT OF SCHIZOPHRENIA IN AUSTRIA

 

Dragosits A, Said M, Walter E
Institute for Pharmaeconomic Research, Vienna, Austria

PMH31

GENETIC TESTING IN COMBINATION WITH PREVENTIVE DONEPEZIL TREATMENT FOR AMNESTIC MILD COGNITIVE IMPAIRMENT PATIENTS: AN EXPLORATORY ECONOMIC EVALUATION OF PERSONALIZED MEDICINE

 

Djalalov S1, Yong J1, Beca J1, Black S2, Saposnik G1, Musa Z3, Siminovitch K4, Moretti M5, Hoch J6
1St. Michael's Hospital, Toronto, ON, Canada, 2Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 3Fred Hutchinson Cancer Research Center, Seattle, WA, USA, 4Mount Sinai Hospital, Toronto, ON, Canada, 5The Hospital for Sick Children, Toronto, ON, Canada, 6Cancer Care Ontario, Toronto, ON, Canada

PMH32

MODELLING THE COST AND EFFECTIVENESS OUTCOMES ASSOCIATED WITH DIFFERENT SEQUENCES FOR THE TREATMENT OF CHRONIC SCHIZOPHRENIA: AN ECONOMIC EVALUATION OF PALIPERIDONE PALMITATE

 

Taylor M1, Shenton R2, Claxton L2, González B3, García I3
1University of York, York, UK, 2York Health Economics Consortium, York, UK, 3Janssen, Madrid, Spain

PMH33

COST EFFECTIVENESS OF PALIPERIDONE PALMITATE VERSUS ORAL MEDICATION IN THE TREATMENT OF SCHIZOPHRENIA IN AUSTRIA

 

Walter E, Dragosits A, Said M
Institute for Pharmaeconomic Research, Vienna, Austria

MENTAL HEALTH – Patient-Reported Outcomes & Patient Preference Studies

PMH34

PERSISTENCE IN USE OF ANTIDEPRESSANTS IN PREGNANT WOMEN ENROLLED IN MEDICAID IN THE UNITED STATES

 

Wu J1, Sykes L2, Keiser S2, Davis-Ajami ML3
1University of South Carolina, Greenville, SC, USA, 2Greenville Hospital System, Greenville, SC, USA, 3University of Maryland, Baltimore, MD, USA

PMH35

EQ-5D UTILITIES AND PRODUCTIVITY OF ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER: REVIEW OF THE LITERATURE AND A CROSS-SECTIONAL SURVEY IN HUNGARY

 

Péntek M1, Gulácsi L1, V. Hevér N1, Papp S2, Baji P3, Brodszky V1, Pulay AJ2, Balogh O1, Bitter I2
1Corvinus University of Budapest, Budapest, Hungary, 2Semmelweis University, Budapest, Hungary, 3Maastricht University, Maastricht, The Netherlands

PMH36

TIME TRADE-OFF (TTO) ANALYSIS TO ELICIT HEALTH STATE UTILITIES RELATED TO LONG ACTING TREATMENTS IN SCHIZOPHRENIA

 

Jensen R1, Sommer KJ2, Søltoft F2, Schmidt A3, Nielsen AT4, Garg M2, Mønsted C5, Bøgelund M5
1Janssen EMEA, Birkerød, Denmark, 2Janssen Cilag, Birkerød, Denmark, 3Janssen Cilag, Sollentuna, Sweden, 4University of Copenhagen, Frederiksberg C, Denmark, 5Incentive Partners, Holte, Denmark

PMH37

SYSTEMATIC REVIEW OF HEALTH STATE UTILITIES IN ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)

 

Zimovetz E1, Setyawan J2, Beard S1, Hodgkins P2
1RTI Health Solutions, Manchester, UK, 2Shire Pharmaceuticals LLC, Wayne, PA, USA

PMH38

ASSESSING DEPRESSIVE SYMPTOMS IN PRIMARY CARE: PSYCHOMETRICAL PROPERTIES OF THE SPANISH VERSION OF THE CLINICALLY USEFUL DEPRESSION OUTCOME SCALE

 

Agüera L1, Monton C2, Maurino J3, Medina E4, Diaz H5, Cuervo J5
1Hospital Doce de Octubre, Madrid, Spain, 2Centro de Salud Casablanca, Zaragoza, Spain, 3AstraZeneca, Madrid, Spain, 4AstraZeneca Pharmaceuticals LP, Madrid, Spain, 5LA-SER (BAP LA-SER Outcomes), Oviedo, Asturias, Spain

PMH39

IDENTIFYING DISEASE-DEFINING CONCEPTS USING SPONTANEOUS AND PROBED RESPONSES FROM SEMI-STRUCTURED QUALITATIVE INTERVIEWS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER

 

McCarrier KP1, Abraham L2, Carpenter LL3, Deal LS4, Thase M5, Trivedi M6, Blum SI7
1Health Research Associates, Inc., Seattle, WA, USA, 2Pfizer Ltd, Walton on the Hill, Tadworth, Surrey, UK, 3Butler Hospital/Brown University, Providence, RI, USA, 4Shire Pharmaceuticals, Wayne, PA, USA, 5University of Pennsylvania, Philadelphia, PA, USA, 6University of Texas Southwestern Medical School, Dallas, TX, USA, 7Forest Research Institute, Jersey City, NJ, USA

PMH40

HOW DO PATIENTS DESCRIBE THEIR DEPRESSION? - INCORPORATING THE PATIENT'S VOICE INTO INSTRUMENT DEVELOPMENT

 

Houle CR1, Blum SI2, Carpenter LL3, Dedios C4, Greco N1, Thase M5, Trivedi M6, Martin ML4, Ramasamy A2
1Abbott Laboratories, Abbott Park, IL, USA, 2Forest Research Institute, Jersey City, NJ, USA, 3Brown University, Providence, RI, USA, 4Health Research Associates, Inc., Seattle, WA, USA, 5University of Pennsylvania, Philadelphia, PA, USA, 6University of Texas Southwestern Medical School, Dallas, TX, USA

PMH41

A CHANGE OF DYSURIA, XEROSTOMIA, ANXIETY AND DEPRESSION AFTER INITIATION OF INHALED DRUGS

 

Hyun MK1, Lee CH2, Jang EJ1, Lee NR1, Kim K3, Yim JJ2
1National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea, 2Seoul National University College of Medicine, Seoul, South Korea, 3National Strategic Coordinating Center for Clinical Research, Seoul, South Korea

PMH42

ASSESSING IMPACTS OF MAJOR DEPRESSIVE DISORDER (MDD) ON COGNITIVE FUNCTION

 

Forsyth B1, Fehnel SE2, Danchenko N3, François C4, Brevig T5
1RTI-Health Solutions, rockville, MD, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3Lundbeck S.A.S., issey-les- moulineaux, France, 4Lundbeck S.A.S., Issy-les-Moulineaux , France, 5Lundbeck S.A.S., issy-les-moulineaux, France

PMH43

MODELLING THE LONGITUDINAL LATENT EFFECT OF PREGABALIN ON SELF-REPORTED CHANGES IN SLEEP DISTURBANCES AND DISABILITY IN OUTPATIENTS WITH GENERALIZED ANXIETY DISORDER (GAD) TREATED IN ROUTINE CLINICAL PRACTICE IN SPAIN

 

Ruiz MA1, Alvarez E2, Carrasco JL3, Olivares JM4, Pérez M5, Rejas J6
1Universidad Autonoma de Madrid, Madrid, Spain, 2Department of Psychiatry, Hospital de la Santa Creu i San Pau, Barcelona, Spain, 3Department of Psychiatry, Hospital Clínico San Carlos, Madrid, Spain, 4Hospital Meixoeiro, Complejo Hospitalario Universitario, Vigo, Spain, 5Department of Neuroscience, Medical Unit, Pfizer Spain, Alcobendas, Madrid, Spain, 6Pfizer España, Alcobendas/Madrid, Spain

PMH44

VALIDITY AND RESPONSIVENESS OF THE EQ-5D AND THE KIDSCREEN-10 IN CHILDREN WITH ADHD

 

Bouwmans C1, Van Der Kolk A2, Oppe M3, Schawo S1, Stolk E1, Van Agthoven M4, van der Gaag RJ5, Buitelaar JB6, Hakkaart-van Roijen L1
1Erasmus University Rotterdam, Rotterdam, The Netherlands, 2Janssen-Cilag BV The Netherlands, Tilburg, The Netherlands, 3iMTA, Rotterdam, The Netherlands, 4Janssen-Cilag BV, Tilburg, The Netherlands, 5Karakter Universitair Centrum, Nijmegen, The Netherlands, 6Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands

PMH45

HEALTH-RELATED QUALITY OF LIFE PATIENT-REPORTED OUTCOMES IN SCHIZOPHRENIA

 

Millier A1, Clay E1, Chauhan D2, Toumi M3
1Creativ-Ceutical, Paris, France, 2Takeda, London, UK, 3University Claude Bernard Lyon 1, Lyon, France

PMH46

DETERMINANTS OF HEALTH-RELATED QUALITY OF LIFE IN JAPANESE PATIENTS WITH CHRONIC SCHIZOPHRENIA

 

Inagaki A1, Inada T2, Yamanouchi Y3, Sukegawa T4, Yoshio T5, Yoshimura R6, Iwata N3
1Institute of Neuropsychiatry, Shinjuku-ku, Tokyo, Japan, 2Institute of Neuropsychopharmacology, Shinjuku-ku, Tokyo, Japan, 3Fujita Health University School of Medicine, Toyoake, Aichi, Japan, 4National Hospital Organization Tottori Medical Center, Tottori, Tottori, Japan, 5Toho University, Funabashi, Chiba, Japan, 6University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan

PMH47

WILLINGNESS TO PAY FOR KEY ATTRIBUTES OF THE NEW LONG ACTING INJECTABLE TREATMENTS IN SCHIZOPHRENIA

 

Jensen R1, Sommer KJ2, Søltoft F2, Schmidt A3, Nielsen AT4, Garg M2, Mønsted C5, Bøgelund M5
1Janssen EMEA, Birkerød, Denmark, 2Janssen Cilag, Birkerød, Denmark, 3Janssen Cilag, Sollentuna, Sweden, 4University of Copenhagen, Frederiksberg C, Denmark, 5Incentive Partners, Holte, Denmark

MENTAL HEALTH – Health Care Use & Policy Studies

PMH48

PUBLIC BELIEFS AND ATTITUDES ABOUT SCHIZOPHRENIA, MAJOR DEPRESSION AND PSYCHOTROPIC MEDICATION

 

Refaï T1, Millier A2, Toumi M3, Rémuzat C2, Angermeyer MC4
1Creativ-Ceutical, Tunis, Tunisia, 2Creativ-Ceutical, Paris, France, 3University Claude Bernard Lyon 1, Lyon, France, 4Center for Public Mental Health, Gösing am Wagram, Austria

PMH49

HORIZON SCANNING OF MOLECULAR IMAGING METHODS IN PSYCHIATRIC DISORDERS

 

Wahlster P, Kriza C, Niederländer C, Schaller S, Kolominsky-Rabas P
University of Erlangen-Nuremberg, Erlangen, Germany

PMH50

DIFFERENCES IN TREATMENT PATTERNS AND CHARACTERISTICS IN PATIENTS WITH BIPOLAR DISORDER - A RETROSPECTIVE REAL LIFE STUDY IN SWEDEN

 

Carlborg A1, Jörgensen L2, Thuresson M3, Bodegård J4
1Stockholm Centre for Psychiatric Research and Education, Stockholm, Sweden, Stockholm, Sweden, 2AstraZeneca, Nordic, Södertälje, Sweden, 3Statisticon AB, Uppsala, Sweden, 4AstraZeneca Nordic, Södertälje, Sweden

PMH51

REAL WORLD ADD-ON AND SWITCH PATTERNS FOR DIFFERENT FORMULATION OF METHYLPHENIDATE

 

Håkan-Mose J, Löfroth E, Huetson P
IMS Health, Stockholm, Sweden

PMH52

HEALTH CARE RESOURCE UTILIZATION AND COSTS FOR PATIENTS WITH ANOREXIA NERVOSA, BULIMIA NERVOSA, AND BINGE EATING DISORDER

 

Supina D1, Lewis-Beck C2, Baser O3
1Shire Development LLC, Wayne, PA, USA, 2STATinMED Research, Ann Arbor, MI, USA, 3STATinMED Research/The University of Michigan, Ann Arbor, MI, USA

PMH53

PREVENTING ALZHEIMER DISEASE: IS THERE A PLACE FOR COST-EFFECTIVE INTERVENTIONS? DYNAMIC MODELING APPLIED TO A PAN EUROPEAN ANALYSIS

 

Roze S1, Vainchtock A2, Marty R1, Galvain T3, Krolak-Salmon P4
1HEVA, Lyon, France, 2HEVA, LYON, France, 3HEVA SAS, LYON, France, 4Hospices civils de Lyon, Villeurbanne, France

PMH54

ADHD AMONG ADULTS IN FIVE WESTERN EUROPEAN COUNTRIES: AN ANALYSIS OF NATIONAL HEALTH AND WELLNESS SURVEY DATA

 

Able SL1, Haynes V1, Annunziata K2, Upadhyaya H1, Deberdt W3
1Eli Lilly and Company, Indianapolis, IN, USA, 2Kantar Health, NY, NY, USA, 3S.A. Eli Lilly Benelux N.V., Bruxelles, Belgium

PMH55

PAYER VALUE IN ALTERNATIVE TREATMENT FORMULATIONS: ACCESS TO NEW MEDICINES IN SCHIZOPHRENIA

 

Morawski J1, Sweeney N2, Nijhuis T1
1Quintiles Consulting, Hoofddorp, The Netherlands, 2Quintiles, Hoofddorp, The Netherlands

PMH56

MOST FREQUENTLY DIAGNOSED MENTAL HEALTH PROBLEMS IN A GERMAN POPULATION

 

Schlander M1, Schwarz O1, Trott GE2, Banaschewski T3, Scheller W4, Viapiano M5, Bonauer N6
1Institute for Innovation & Valuation in Health Care, Wiesbaden, Germany, 2University of Wuerzburg, Aschaffenburg, Germany, 3University of Heidelberg, Mannheim, Germany, 4Verband der Ersatzkassen (vdek), Stuttgart, Germany, 5KV BaWue, Karlsruhe, Germany, 6KV Baden-Wuerttemberg, Karlsruhe, Germany

PMH57

HTA LANDSCAPE OF TREATMENTS AVAILABLE FOR ALCOHOL-RELATED DISORDERS

 

Andreykiv M1, Schuchardt M1, Laramée P2
1Quintiles, Hoofddorp, The Netherlands, 2Lundbeck S.A.S., Issy-les-Moulineaux cedex, France

PMH58

THE IMPACT OF ADHD MEDICATION ATTRIBUTES ON PHYSICIAN PRESCRIBING BEHAVIOR IN THE EU: RESULTS FROM CHART-REVIEWED DATA

 

Fridman M1, Katic B2, Setyawan J2, Hodgkins P2, Erder MH2
1AMF Consulting, Los Angeles, CA, USA, 2Shire Pharmaceuticals LLC, Wayne, PA, USA



15th Annual European Congress Index Page